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ABSTRACT 
 
 
 Using prior biological data, pharmacophore models were made for hCNT1, 
hCNT3, hENT1, and hENT4. The hCNT3 and hCNT1 pharmacophore were used to 
select compounds for biological testing. The NBMPR analogue and dipyridamole 
analogue hENT1 pharmacophores were compared to each other and to a combined 
pharmacophore for hENT1. The dipyridamole analogue pharmacophore better predicted 
non-nucleoside small molecule inhibitors, and as such appears to be the better tool for 
aiding in the design of new small molecule inhibitors. The hCNT3 pharmacophore failed 
to select active compounds and as such must be redesigned. The hCNT1 pharmacophore 
succeeded in identifying two moderately active compounds and when the hits were added 
into the data set to make a new pharmacophore, a more statistically valid model was 
achieved. The hCNT1 model is a statistically valid model for in silico screening of 
compounds. 
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CHAPTER 1.    INTRODUCTION 
Classification of Nucleoside Transporters 
Nucleosides (Figure 1-1) act as building blocks for DNA, RNA, energetic 
precursors, regulate energy metabolism, and specifically in the case of adenosine, act as 
second messengers, regulating a variety of cellular functions.2, 3 Before the human 
genome project, our understanding of cells and how they take up nucleosides was based 
on kinetic experiments in the 1980’s.4  The literature still sometimes reflects the 
nomenclature adopted for the nucleoside transporters at that time. Long before we knew 
the gene sequences, scientists showed two classes of membrane proteins, one which acted 
in an equilibrative manner and another which transported purine and pyrimidine 
nucleosides against the concentration gradient. In addition, further classification divided 
the equilibrative based on the sensitivity to inhibition by S-(4-nitrobenzyl)-6-
mercaptopurine riboside (NBMPR), designating the two equilibrative transporters as 
equilibrative sensitive (es) and equilibrative insensitive (ei).5Similarly, the concentrative 
transporters were designated as concentrative inhibitor insensitive and utilizing formycin 
B as a substrate (cif) or concentrative inhibitor insensitive and utilizing thymidine as a 
substrate (cit).5 Literature from that era differs in the consensus on the exact number of 
transporters in each family. Today, thanks to genetic sequencing, seven nucleoside 
transporters have been identified, four equilibrative and three concentrative, with 
differing substrate specificities and transport efficiencies.6 We now refer to the 
concentrative family as solute carrier 28 (SLC28) and the equilibrative family as solute 
carrier 29 (SLC29), with the isoforms designated as ENT1/2/3/4 and CNT1/2/3, 
respectively.6  
Nucleoside Transporter Substrate Specificity 
While both families of transporters move nucleosides and synthetic analogues 
across cellular membranes, they are not evolutionarily related.7 Both families evolved 
early with CNTs being found in eukaryotes and eubacteria.3 That evidence, combined 
with the widespread ENT orthologs in eukaryotes, suggests their vital roles in cellular 
functions. Numerous studies over the past decades have elucidated their actions in the 
uptake of endogenous purines, pyrimidines, nucleobases, and chemotherapeutic drugs.2 
The CNT family operates in a sodium dependent manner against the 
concentration gradient, with CNT18 and CNT29 requiring one to one sodium to 
transporter stoichiometry for every nucleoside transported, whereas CNT3 uses either 
two molecules of sodium for every nucleoside or a one each sodium and proton for 
transfer of one nucleoside molecule across the cell membrane.2 The recently published 
crystal structure of the Vibrio cholerae CNT, which is 36% and 37% percent homologous 
to hCNT1 and hCNT2, respectively and 39% identical to hCNT3, suggests that the 
vcCNT  functions as a trimer.10 It remains to be seen whether that is true and if their 
hypothesis extends to the human orthologs. hCNT3 is an efficient transporter with broad 
permeant selectivity.11 In contrast hCNT1 transports primarily pyrimidines and their  
. 
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Figure 1-1. Natural nucleosides 
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3 
synthetic analogues while hCNT2 transports purines and synthetic purine analogues; 
however, both transport adenosine (purine) and uridine (pyrimidine), albeit at lower 
efficiency.9 The different concentrative isoforms are primarily located on the plasma 
membrane, but some cells have been found to have internal hCNT3 and a functional 
splice variant that is retained within the endoplasmic reticulum has been identified.12  
In contrast, the equilibrative family moves their substrates across the membrane 
via facilitated diffusion, either with (ENT3/ENT4) or without (ENT1/ENT2) the aid of a 
proton.6 Historically, hENT2 has proven more resistant to classical inhibitors  
(Figure 1-2). Both ENT1 and ENT2 have broad permeant selectivity, transporting both 
purines and pyrimidines, with ENT2 to a lesser extent also transporting nucleobases.6 
However, recent evidence indicates that hENT1 is also capable of transporting 
nucleobases, but at a much lower efficiency.13 While kinetic experiments in mammalian 
cells suggest a nucleobase specific sodium-dependent mechanism for cellular uptake, to 
date no human nucleobase transporter proteins have been isolated.2 As such, this 
highlights the importance of the nucleoside transporters for both nucleoside and 
nucleobase salvage and in the uptake of drugs targeting biological pathways utilizing 
them.  
Both hENT1 and hENT2 are primarily found on the plasma membrane, but are 
also found on the nuclear membrane. In addition, ENT1 has been found on the 
mitochondria.6 The presence in mitochondrial membranes does not appear to be general 
across mammalian species. For example, rats do not express ENT1 on their mitochondrial 
membrane.6 ENT3, which is found primarily on the lysosome, endosome, and 
mitochondria, has not to date been reported as expressed on the plasma membrane and 
appears to function primarily as an intracellular transporter.6 It transports purines, 
pyrimidines, and nucleobases, but not hypoxanthine, which ENT2 transports.6 In 
addition, the reported Kms for endogenous substrates are higher in comparison to ENT1 
and ENT2.6 This difference in Km could potentially exist as a regulation mechanism so 
that as ENT1 and ENT2 take up nucleosides, they are not disproportionately taken up by 
the lysosomes before they can be utilized.  
Lastly, differing significantly in sequence similarity and substrates, ENT4 is 
primarily located on the plasma membrane and transports monoamines at physiological 
pH. Wang et al14 postulates that ENT4 is more closely related in function under normal 
physiological conditions to the PMATs (poly monoamine transporters), transporting 
serotonin and dopamine in the brain, with adenosine and other nucleoside transport being 
incidental. However, sufficient data exists that under ischemic acidic conditions, the local 
pH can drop into a range in which hENT4’s transport of adenosine and other nucleosides 
would be significant.15, 16  
Transporter Structure and Biological Distribution 
Both transporter families are transmembrane proteins, but they differ in length. 
While we do not yet have crystal structures to definitively elucidate their biological  
. 
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Figure 1-2. Classic nucleoside inhibitors 
  
Note:  (A) S-(4-Nitrobenzyl)-6-thioinosine (NBMPR), (B) dipyridamole 
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5 
conformations, similarity to other protein families and a number of molecular biological 
experiments have outlined their theoretical structures.  
In 1997, Young et al. cloned the human gene for CNT1.17 Located on 
chromosome 15q25-26, it is 83% homologous to its rat ortholog, and codes for a 690 
amino acid protein.17 Originally, scientists proposed a fourteen transmembrane model,18 
but later revised the model to thirteen transmembrane regions.19 However, in 2009, 
another group put forth a fifteen transmembrane model based on a newer molecular 
modeling method.20 In short, the exact topologies of the CNT transporters remain 
unverified. 
Not long after, the 659 amino acid protein for hCNT2 was cloned and localized to 
chromosome 15q15, followed the 691 amino acid protein for hCNT3, on chromosome 
9q22.2.3 The human isoforms share less similarity with each other than they do with other 
species orthologs. For example, hCNT1 is 71% homologous to hCNT2, but as mentioned, 
83% rCNT1. hCNT3 shares even less homology at 48% and 47% sequence similarity to 
hCNT1 and hCNT2, respectively.3 This, in addition to their presence in bacteria, suggests 
highly conserved function, vital to cellular processes. 
The sequences of hENT1 and hENT2 were determined in 1996, but hENT3 and 
hENT4 were not sequenced for close to a decade after that.7 Both hENT1 and hENT2 are 
456-amino acid proteins sharing 46% homology.7 The intracellular hENT3 is coded by a 
475 amino acid sequence and shares only 29% homology with hENT1.7 The last protein 
in the ENT family, and arguably the most evolutionarily distant, is coded by 530 amino 
acid protein and is only 18% homologous to hENT1. Experiments have confirmed a 
proposed 11 transmembrane topology,7 highlighting another difference between the CNT 
and ENT families.  
Together these two families function to maintain homeostasis. As such, they have 
different biological distributions. Table 1-1 outlines the predominant tissues in which 
each of the transporters is found. 
It is not uncommon to find ENTs on one side of a cell and CNTs on another side, 
especially in organs such as the intestines, liver, kidneys, and brain. Figure 1-3, which 
was published in a recent review illustrates some of the arrangements of nucleoside 
transporters found to date.2 
While altered expression of nucleoside levels have been shown in a number of 
disease states, with only one exception, no specific pathology is directly linked to 
nucleoside transporter mutations. Hystiocytosis syndrome and Rosai-Dorfman disease are 
two lysosomal storage diseases with overlapping phenotypes which are directly linked to 
germ line mutations of hENT3.21 The mutations alter the function of hENT3 or result in a 
nonfunctional protein. In vitro studies suggest hENT3 plays a role in regulating cell 
growth and proliferation and that in its absence cells experience aberrant growth and 
proliferation.21 Still, the exact method of pathogenesis requires further elucidation.  
Table 1-2 lists known mutations, many of which alter permeant kinetics. Their effects on 
disease and drug metabolism are still being explored, but preliminary studies indicate that  
. 
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Table 1-1. Nucleoside transporter tissue distribution in humans 
 
Transporter  Tissue 
ENT1  Widely expressed. Found on the plasma membrane 
of most tissues, also on nuclear membranes and 
mitochondrial membranes. 
ENT2  Widely expressed, with more abundance in skeletal 
tissues. Found primarily on plasma membranes, but 
also detected on some nuclear membranes. 
ENT3  Widely expressed, intracellular. 
ENT4  Plasma membrane, heart, brain, and skeletal muscle. 
CNT1  Specialized epithelial cells: kidney, liver, intestines, 
plasma membrane. 
CNT2  Plasma membrane, heart, skeletal muscle, liver, 
kidney, intestine, pancreas, placenta, and brain. 
CNT3  Mostly plasma membrane, but intracellular in some 
cells. Located in most abundance in mammary 
glands, pancreas, bone marrow, trachea, and 
intestines, but found throughout body. 
 
Reprinted with permission from Elsevier. Young, J. D.; Yao, S. Y. M.; Baldwin, J. M.; 
Cass, C. E.; Baldwin, S. A. Molecular Aspects of Medicine 34 (2013) 529–547. 
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Figure 1-3. Graphical depiction of human nucleoside transporter distributions 
 
Note: Abbreviations used in this Figure are: (A, B) apical membrane (AM), basolateral 
membrane (BM); (C) canalicular membrane (CM), sinusoidal membrane (SM); (D) 
blood–brain barrier endothelial cells (BBB), blood-cerebrospinal fluid barrier epithelial 
cells of the choroid plexus (BCSFB), interstitial fluid (IF), cerebrospinal fluid (CSF), 
abluminal (IF-facing) membrane of the BBB (ABM), luminal (blood-facing) membrane 
of the BBB (LM), apical (CSF-facing) membrane of the BCSFB (AM), basolateral 
(blood-facing) membrane of the BCSFB (BM). 
 
Reprinted with permission from Elsevier. Young, J. D.; Yao, S. Y. M.; Baldwin, J. M.; 
Cass, C. E.; Baldwin, S. A. Molecular Aspects of Medicine 34 (2013) 529–547. 
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Table 1-2. Current known nucleoside transporter mutations 
 
Transporter Mutations 
ENT1 ? Single missense point mutation at glycine 24 (cancer cell 
line)37 
ENT2 ? Exon 4 splice variant leading to N-terminally truncated, 
inactive protein (HNP36)2 
? Exon 9 splice variant leading to C-terminally truncated, 
inactive protein (ENT2A)2 
ENT3 ? M116R 
? G427S 
?  G437R 
? T449R 
? various frameshift mutations 
All abolish or reduce transport activity, cause mistrafficking, 
or protein instability 
Associated with H, FHC and PHID syndromes and Rosai-
Dorfman disease2, 21 
ENT4 ? None reported to date 
CNT1 ? S546P 
? V189I 
? 1153del38 
CNT2 ? F355S 
? E385K39 
CNT3 ? Splice variant CNT3ins lacks the N-terminal 69 residues and 
is retained in the endoplasmic reticulum (still functional)12  
? Gly367Arg40 
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variants can contribute to altered uptake of chemotherapeutics as well as endogenous 
substrates. Likewise, it is not fully understood why so many cells express various 
transporters, resulting in overlapping permeant selectivity. Perhaps, as they tie in directly 
to the scavenging of molecules required for DNA replication, evolution resulted in 
redundancies, which aid in cellular survival, but a great deal of further research is needed 
to confirm or refute that speculation.   
Nucleoside Transporters and Species Variations 
Animal models have elucidated a number of potential roles that nucleoside 
transporters play. In Drosophila fruit flies, DeENT2 was shown to regulate cognitive 
learning and that the null mutant was lethal.22 In contrast a null ENT1 mouse model 
demonstrated a link between alcohol sensitivity and ENT1, suggesting that it played a 
role in intoxication.23  Otherwise, ENT1 null mice appeared healthy. While these and 
other findings might hold true in humans, one cannot assume that every animal model 
directly correlates to human biology.  
Despite the high degree of similarity and function of the nucleoside transporters, 
species differences do exist. For example, rat ENT1 and ENT2 are more resistant to 
inhibition by the same molecules that inhibit the human orthologs at nanomolar 
concentrations.7 When utilizing cells for assays, rat or mouse results may not translate to 
human activity and vice versa. Even tissue distributions vary from species to species. For 
example, mice and rats, both rodents, express different amounts of CNT2 in their livers, 
implying potentially vastly different pharmacokinetics of nucleoside chemotherapeutic 
drugs.24 Rats expressed high amounts of hepatic rCNT2, but mice had no measurable 
hepatic mCNT2.24 When designing animal in vivo studies of nucleoside transporters, one 
must keep species variance in mind as results may not always translate to human systems.  
Known Inhibitors of Nucleoside Transporters 
Broadly speaking, known nucleoside transporter inhibitors can be divided into 
two categories: nucleoside analogue inhibitors and non-nucleoside analogues. Of all the 
transporters, hENT1 appears to be most easily inhibited by a variety of molecules. It 
should also be noted that the literature identification of inhibitors and reported potencies 
can vary depending on the species of cell used and even on cell type. 
 
hENT Inhibitors 
 
Belonging to the 9-?-D-ribofuranosyl purine class (Figure 1-2) NBMPR was 
identified in 1974 as a potent inhibitor of hENT1, inhibiting at nanomolar concentrations 
and is often used as the reference standard today.25 Due to mutagenicity, 
immunosuppressive properties,26 and poor pharmacokinetics it has limited potential as a 
clinical agent. 27 In the nearly four decades since, a wide variety of nucleoside analogues 
and small molecules have been found to inhibit hENT1, although potency varies. 
. 
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NBMPR belongs within the category of nucleoside analogues. Within that category, one 
also finds cyclic adenosine mono-phosphate (cAMP) derivatives.28 
A number of the small molecule inhibitors fit into either purine or pyrimidine 
analogues, which is logical as hENT1 transports these and the functionality would be the 
source of affinity for the molecules. Table 1-3 lists some examples of the variety of 
molecules that have been found to inhibit hENT1. 
Table 1-3 is by no means an exhaustive list, but rather represents examples of the 
most potent chemical classes identified to date.  Some of the compounds listed, such as 
dipyridamole and dilazep also inhibit hENT2, albeit with Kis several fold higher.29 
Hammond et al. identified draflazine analogues (Figure 1-4) which showed hENT2 
selectivity.30 In addition, a number of dipyridamole analogues were synthesized which 
demonstrated hENT2 selectivity.31  While these compounds are promising, the 
identification of hENT2 potent and selective inhibitors remains a challenging obstacle to 
fully exploring the cell signaling role of this transporter.  
 
Far fewer studies have been conducted on hENT3 due to its intracellular location 
and the difficulty of isolating functional proteins. The studies that have been conducted 
demonstrate that it is resistant to traditional hENT inhibitors and its functionality is pH 
dependent.32 
Like hENT3, hENT4 nucleoside transport is pH dependent and weakly inhibited 
by traditional inhibitors like NBMPR and dipyridamole.16 However, recently published 
work showed a series of dipyridamole analogues which demonstrated hENT4 selectivity 
and potency.1 Figure 1-5 illustrates the structure of the most potent analogue WL30.1 
 
hCNT Inhibitors 
 
In contrast to the equilibrative transporters, there have been far fewer inhibitors 
identified for the concentrative transporters. One group identified a class of purine 
nucleoside derivatives with 8-position modifications as selective hCNT2 inhibitors 
(Figure 1-6).33 
In 2014 another group reported that several chemotherapeutic agents inhibit 
nucleoside transporters, including concentrative transporters, at varying micromolar 
concentrations (Table 1-4). 
 
As Figure 1-7 shows, these are non-nucleoside structures, but their toxicity and 
non-specific action make them poor tools for studying nucleoside transporters. Another 
compound, traditionally used as a pan-inhibitor of concentrative nucleoside transporters 
is phlordizin (Figure 1-8).34 A natural product isolated from apple wood and other plants, 
it also inhibits sodium/glucose co-transporters one and two (SGLT1 and SGLT2).35 Its 
inhibitory Kis of the CNTs measures at or greater than 17?M for all of the isoforms, 
highlighting its lack of potency and selectivity.34, 36 Of the three CNT transporters, it 
demonstrates the highest potency against hCNT3. With that in mind, Gupte et al.  
. 
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Table 1-3. Survey of non-nucleoside inhibitors of ENT1 
 
Chemical Class Example Structure IC50 nM 
Pyridinyl 
imidazoles 
SB203580-
iodo 
 
689.4 ± 
222.241 
Pyrimido 
pyrimidine** 
Dipyridamole 
 
48*42 
Thiazolindedion
es 
Troglitazone 
 
2350 ± 35043 
Xanthine 
Oxidase 
Inhibitors 
Febuxostat 
 
4100*44 
Diazepane and 
Piperazines 
Dilazep 
 
18.7 ± 242 
 
 
. 
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Table 1-3. Continued 
 
Chemical Class Example Structure IC50 nM 
Diazepane Dilazep 
 
18.7 ± 242 
Dihydropyridines 
(Calcium channel 
blockers) 
Nimodipine 
 
20045 
 
Note: *reported Ki value. **Includes pteridine derivatives46 
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Note: Draflazine is hENT1 selective while soluflazine shows greater hENT2 affinity.30 
  
 
 
A 
 
B 
Figure 1-4. (A) Draflazine and (B) soluflazine  
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Figure 1-6. 8-position modified purine analogue 
 
 
 
Table 1-4. Micomolar/L IC50 of uridine transport in yeast 
 
Transporter Erlotinib Gefitinib Vandetanib 
hENT1 34 ± 6 14 ± 2 11 ± 1 
hENT2 >300 >300 89 ± 17 
hCNT1 160 ± 20 37 ± 11 64 ± 17 
hCNT2 > 300 >300 82 ± 4 
hCNT3 11 ± 1 >300 28 ± 9 
 
Reprinted with permission from Elsevier. Damaraju, V. L.; Scriver, T.; Mowles, D.; 
Kuzma, M.; Ryan, A. J.; Cass, C. E.; Sawyer, M. B. Clinical Cancer Research 2014, 20, 
176. 
 
 
 
 
Figure 1-5. WL30 a potent and selective hENT4 inhibitor 
. 
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Note: (A) Erlotinib (B) Gefitinib (C) Vandetanib  
 
 
 
 
 
 
 
 
A 
 
B 
 
C 
Figure 1-7. Chemotherapy agents with nucleoside transporter inhibitory activity 
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A 
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Figure 1-8. (A) Phlorizin (B) phlorizin analogue  
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synthesized a series of analogues, successfully making a derivative with higher potency.34 
With a Ki of 2.88 ?M,34 it shows a marked increase in potency, but the furanose ring is 
less than optimal for drug design.  
Nucleoside Transporter Inhibitor Applications and Purpose of Study 
Small molecule, selective inhibitors can assist in our examinations of cell 
signaling and the roles nucleoside transporters play on homeostasis as well as pathogenic 
states. Many of the drugs currently used as cancer chemotherapy agents,48 in addition 
antiretrovirals49 are transported by nucleoside transporters.  In addition, it has been well 
established that nucleoside transporters modulate extracellular adenosine and during 
ischemic events extracellular adenosine can effect cell survival during reperfusion.50, 51 
While the exact molecular mechanisms of this are still being elucidated, it suggests that 
nucleoside transporters can be utilized for uses such as cardio-, neuro-, or renal protection 
during ischemic events.  
Cancer chemotherapy, in which nucleoside transporters play a role in both uptake 
and efflux of drugs and endogenous nucleosides, is hampered by changes in cellular 
expression and toxicity to healthy cells. The use of viral vectors, while effective to 
selectively target cancer cells, has limited in vivo efficacy due to poor spread and 
replication, however a recent study showed that use of nucleoside transporter inhibitors 
could increase their potency.52 The oHSV1 vector is transfected to express an oncolytic 
gene. The nucleoside inhibitors likely increase their efficacy by preventing the salvage of 
nucleosides and nucleobases. The viral vector uses up the available nucleosides within 
the cell for replication, leaving the cancer cell short on the critical components necessary 
for DNA replication. 
Furthermore, adenosine is implicated in modulating immune function and 
inflammation.53, 54 As such, further exploration of the role of nucleoside transporters in 
modulating inflammation could bring new understanding to the field.  
Humans and other mammals can synthesize nucleosides in most of our tissues, 
whereas many bacteria rely on salvage. Species differences also allow for selective 
targeting of non-mammalian transporters. Nucleoside transporters are a novel target for 
those focusing on pathogenic agents, such as malaria or bacteria.55, 56     
Without selective, potent small molecule inhibitors, we cannot further our 
knowledge of vital cell signaling pathways. Likewise, the potential applications cannot be 
explored. While there are a number of small molecule hENT1 inhibitors, ones that enter 
the CNS are still needed, and the other transporters lack diverse, potent, and selective 
molecular inhibitors.  
It was the goal of this study to utilize computer-aided drug design, synthesis, and 
cell-based screening to identify novel scaffolds for each of the nucleoside transporters, 
with the exception of hENT3, for further study.    
. 
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CHAPTER 2.    COMPUTER MODELING STUDIES 
Introduction 
There are two primary approaches to computer-aided drug design and discovery: 
structure based and ligand based. Structure based methods require a crystal structure or a 
homology model based on a similar protein, or a structure determined by other methods 
such as NMR. In ligand based methods, the researcher aims to correlate structural 
features of active and inactive molecules with biological activity. While there are a 
number of methods, this study focused on three quantitative structure-activity 
relationship (QSAR) methods: comparative field analysis (CoMFA),57 comparative 
similarity indices analysis (CoMSIA),58 and pharmacophore (3D QSAR).59 The concept 
of a pharmacophore, or structure features of a molecule required for bioactivity, was 
developed by Lemont Kier, and has greatly advanced in the four decades since he first 
described it. Pharmacophore 3D QSAR can be used alone to digitally screen databases 
for potential bioactive molecules or in concert with CoMSIA and CoMFA as an 
alignment method.60 While, these methods were primarily used for the selection of 
compounds for screening against the concentrative transporter, in 2012 a crystal structure 
of a Vibrio cholera transporter was published.10  The V. cholera and hCNT1 shared 
enough similarity that Dr. Hemantkumar Deokar of our laboratory created a hCNT1 
homology model (unpublished). Both the V. cholera crystal structure and homology 
model were used by him to select two sets of the compounds presented in this study. 
A number of key assumptions underlie 3D QSAR methods.61 
1. The ligands all bind at the same location and in the same mode. 
2. The conformation(s) of the molecules in the database are the bioactive 
conformations. 
3. There is negligible difference in entropic factors. 
4. Biological activity results primarily from enthalpic contributions. 
5. That the biological measurements are made without error. 
6. The system is at equilibrium. 
7. Solvent effects, transport and diffusion are not important to biological activity. 
 
 Understanding the underlying assumptions can help to interpret why a model 
performs poorly and perhaps why specific compounds are “outliers” (i.e. predicted far 
outside the expected data range). Also 3D QSAR does not account for conformational 
changes which occur as the ligand binds to the transporter, which current biological 
studies suggest likely occur and that it is not the binding of the inhibitor, but rather the 
increased Km of the translocation step which is key to inhibition.62 This implies that there 
will be limitations to 3D modeling, which is where the homology model can potentially 
improve success of novel inhibitor discovery and design.  
Past molecular modeling studies have primarily looked at nucleoside analogues. 
(See Figure 2-1 for nucleoside position numbering.) They found that the ribose ring was 
favored over other sugars, the 3’ position of the ribose ring or an isostere in which a  
. 
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Figure 2-1. Nucleoside numbering on (A) purine and (B) pyrimidine 
 
  
  
 
A    B 
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hydrogen bond donor and accepting group occupied the same space was required for 
hENT1 activity. Similarly both hCNT1 and hCNT2 required the H-bond acceptor at 3’C 
and at the 2 position of the pyrimidine ring, but only hCNT2 seemed to require a H-bond 
acceptor at 5’.  hCNT2 seemed to involve primarily H-bond interactions while hCNT1 
utilized electrostatic and steric interactions as well.63 Two studies64, 65 described 3D 
QSAR results of NBMPR analogues and their interaction with hENT1 which not only 
agreed with prior research, but correlated with an NMR study66 which demonstrated an 
anti-configuration rather than the syn configuration seen in X-ray diffraction and  X-ray 
crystals of NBMPR.67, 68 
Ho et al did a study on hENT4 in which they looked at substrate and inhibitor 
structure-activity relationships at physiological pH.69 A hydrophobic aryl group spaced 
0.5 to 7.7 Ǻ appeared to be key, with IC50s decreasing with increasing hydrophobicity.69 
It is important to note that the IC50 range of the substrates and inhibitors tested ranged 
from roughly 9 ?M to upwards of 1000 ?M or more. In contrast, Wang et al., which 
looked at hENT4 activity under the acidic conditions one might find in ischemic 
conditions identified potent nanomolar dipyridamole derivatives.1 The QSAR studies for 
that biological set is presented in this work. 
Another modeling study looked at benzopyranone derivatives and related 
compounds and their interaction with the concentrative nucleoside transporters.70 It 
identified the molecules used in the creation of the pharmacophore models that will be 
presented in this work. While the CoMFA and CoMSIA models presented highlighted the 
interactions necessary for potency within that scaffold, and can predict potency for 
similar molecules, it is less adept at identifying new scaffolds, which was the goal of the 
pharmacophore models. 
Finally, Hu et al. examined hCNT3 with CoMFA and CoMSIA and determined 
that electrostatic interactions played the role in hCNT3 substrate affinity, with the 
3’hydroxyl being a key structural feature.71 In addition, they determined that steric 
hindrance at the 3-position and a positive charge at the 5-positition were favorable for 
hCNT3 transport.71 When they looked at pharmacophore features, the minimum required 
for substrate transport by hCNT3 was a hydrogen bond acceptor at 3’-OH and 5’-O in 
addition to a hydrophobic center in the position of the pyrimidine base ring.71 
It is important to note that a number of prior studies focus on substrates or do not 
differentiate between substrates and inhibitors. Ideally, when designing an inhibitor it 
will retain affinity, binding tightly, but prove to be a poor substrate, thus inhibiting the 
transporter. This suggests that the pharmacophore for competitive inhibitors would 
encompass that of substrates, but contain another element(s). Once enough diverse, 
potent, and selective inhibitors are identified, that is an area that requires exploration. 
Experimental Methods 
Schrodinger’s Maestro modeling suite was used to build a database of 
molecules.72  After which, the PHASE module was used to minimize, generate 
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conformers, identify pharmacophore elements, and generate hypotheses using default 
settings.73 Hypotheses were scored by fit and selected based on the pharmacophore’s q2 
statistics. For data sets in which CoMFA and/or CoMSIA models were generated, the 
resulting hypothesis and molecular alignments were exported into Sybyl X74 where 
CoMFA and CoMSIA descriptors were generated and PLS models were established. 
CoMFA and CoMSIA models were validated by leave-one-out cross-validation, and 
external test sets. External test sets were chosen by ranking the data set according to 
activity. Then every eleventh compound, which equated to approximately ten percent of 
the database, was selected to comprise a representative selection of molecules of varying 
activity. For in silico screening, the pharmacophore hypothesis in PHASE was used to 
screen the University of Cincinnati’s proprietary database of about 360,000 small 
molecule compounds. Compounds were initially cherry picked for novel structure (CNT3 
model). One hundred and ninety-two compounds were selected for biological testing. 
For the CNT1 model, a 500 molecular weight cut off was applied and hits were 
ranked according to predicted -Log IC50.  Excluding compounds of flavonoid like 
structures or nucleoside structures, or molecules containing functional groups such as 
carboxylates which have never demonstrated high nucleoside transporter affinity, the top 
ninety-six compounds were selected for biological testing. 
 
 
Results 
 
 
hENT1 Models 
 
In an attempt to explore the structure-activity relationship of benzopyranone 
(flavonoid) analogues with nucleoside transporters, biological data from the Wang et al. 
study was used to develop a pharmacophore hypothesis.70 The three most active 
compounds were used define “active” and three compounds with much higher IC50s were 
used to define “inactive” (Figure 2-2). 
The hypothesis (Figure 2-3) was used to align the database. By itself, it had poor 
predicative capability. Table 2-1 shows the CoMFA statistics. The flavonoid compounds 
were not particularly potent, and the compounds were of high similarity, neither of which 
is ideal for producing a robust model. 
 The CoMFA model indicates that both steric and electrostatic interactions play a 
role in the binding of the flavonoid ligands to the hENT1 transporter. Figure 2-4 shows 
the residuals plot, with the actual –Log IC50s on the x-axis and the predicted –Log IC50s 
on the y-axis. The spread of the test set is a little wide, which suggests that the model is 
perhaps slightly over fit. Given the poor predictive capability of the pharmacophore and 
the CoMFA model and the inability to identify a statistically significant CoMSIA model, 
the flavonoids proved of little use in terms of identifying a useful pharmacophore. 
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Figure 2-2. Flavonoid active and inactive sets used for the creation of ENT1 
pharmacophore 
 
 
 
 
 
Figure 2-3. Flavonoid ENT1 5-point pharmacophore hypothesis 
 
Note:  Light blue spheres indicate hydrogen bond donor, red spheres are hydrogen bond 
acceptors, and orange rings are aromatic rings. 
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Table 2-1. Flavonoid hENT1 CoMFA statistics 
PLS Statistics hENT1 CoMFA 
q2 (LOO*) 0.460 
r2 0.888 
S 0.130 
F 61.544 
PLS components 4 
No. of compounds used for model 36 
No. of outliers 6 
No. of compounds in external test set 4 
Steric descriptor contribution 0.519 
Electrostatic descriptor contribution 0.481 
 
Note: Leave one out (LOO)* 
 
 
 
  
 
Figure 2-4. Predicted versus actual –Log IC50 of flavonoid analogues 
. 
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Similarly, models were created for both dipyridamole analogues and NBMPR 
analogues. Figure 2-5 and Figure 2-6 show the structures of the compounds used to 
generate the pharmacophore models. 
In addition, a small series of new nucleoside analogues were synthesized  
(Chapter 3) and tested. Of the four active molecules the NBMPR model predicted two 
within one log unit, and three within 1.3 log units. HCPN05 possessed activity over two 
log units lower than predicted (Figure 2-7), potentially due to lack of representation in 
the training set. Residual plots for the NBMPR models can be seen in Figure 2-8 and 
Figure 2-9. 
 
Figure 2-10 illustrates the pharmacophores which were used to align the models. 
Both the nucleoside and dipyridamole models were statistically significant. While the 
NBMPR models resulted in higher q2s, they also had higher deviation about the 
regression line when compared to the dipyridamole models, suggesting that the NBMPR 
model is slightly over-fit. Comparing the PLS statistics in Table 2-2 it is of particular 
interest that both CoMSIA models arrive at nearly the same hydrophobic descriptor 
contribution, and similar hydrogen bond acceptor contributions, but differ greatly on the 
contribution of hydrogen bond donor interactions. Figure 2-11 and Figure 2-12 illustrate 
the compounds used to design the pharmacophore and Figure 2-13 shows the resulting 
pharmacophore. Given the results, the question then, was this a real difference, or an 
artifact of an over fit model? 
Molecular studies in the literature indicate that while NBMPR and dipyridamole 
demonstrate competitive inhibition of each other, they do not likely bind to the exact 
same site on hENT1.75 Perhaps the difference in the hydrogen bond donor contributions 
accounted for this difference in binding. With this in mind, a pharmacophore model was 
produced using all of the compounds in the prior three studies, and that model was used 
to create CoMFA and CoMSIA models. As expected, the resulting model performed 
poorly in comparison to either of the NBMPR or dipyridamole models, reflecting that 
each of these models displayed statistically significant interactions that did not correlate 
with each other (Table 2-3). This also suggested that more than one binding location did 
in fact exist. The next step involved identifying which model had better predictive 
capability in identifying small molecule biologically active molecules.  
While not quite the same as the dipyridamole model, it is interesting to note that 
that the hydrogen bond donor and acceptor contributions of the combined model 
compared more closely to that model than the NBMPR model.  
To test the individual models, the structures of diverse compounds that had shown 
up as “hits” in a cellular screening assay, and for which IC50 data had been calculated, 
were put into a database. Since, flavonoids have a number of drawbacks, namely poor 
potency and poor biological selectivity. They hit a wide variety of biologically relative 
targets. In addition flavonoids have been widely examined and shown to have little room 
for chemical alterations. Thus, it was decided not to pursue them as leads. Given that the 
model did not perform as well, it was not included in the model comparison. 
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Figure 2-5. Dipyridamole analogues used for the creation of hENT1 
pharmacophore 
 
 
 
 
 
  
 
Figure 2-6. Active nucleoside analogues used for hENT1 pharmacophore 
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Figure 2-7. Synthesized nucleoside analogues 
 
 
 
 
 
 
 
 
Figure 2-8. Prediction plot of hENT1 NBMPR CoMFA model 
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Note:  Light blue spheres indicate hydrogen bond donor, red spheres are hydrogen bond 
acceptors, orange rings are aromatic rings, and blue squares indicate favorable 
interactions for high potency in regards to the ligand’s fit and the hypothesis. Blue boxes 
were emitted in (B) as their quantity obscured the pharmacophore points. 
 
  
 
Figure 2-9. Prediction plot of hENT1 NBMPR CoMSIA model 
 
  A     B 
Figure 2-10. NBMPR (A) pharmacophore and dipyridamole (B) pharmacophore 
. 
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Table 2-2. Dipyridamole and NBMPR analogue pharmacophore aligned models 
 
PLS Statistics 
Dipyridamole 
CoMFA 
Dipyridamole 
CoMSIA 
NBMPR 
CoMFA 
NBMPR 
CoMSIA 
 
q2 (LOO) 0.479 0.442 0.525 0.573 
r2 0.975 0.949 0.938 0.949 
S 0.107 0.152 0.334 0.302 
F 249.576 120.637 161.053 199.655 
PLS components 6 6 6 6 
Number of compounds used 
for model 46 46 70 70 
Number of outliers 7 6 4 4 
Number of compounds in 
external test set 5 5 35 35 
Steric descriptor contribution 0.398 0.077 0.510 0.132 
Electrostatic descriptor 
contribution 0.602 0.213 0.490 0.360 
Hydrophobic descriptor 
contribution N/A 0.287 N/A 0.286 
H-bond donor descriptor 
contribution N/A 0.289 N/A 0.098 
H-bond acceptor descriptor 
contribution N/A 0.134 N/A 0.124 
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Figure 2-11. Active set for ENT1 “combined” pharmacophore 
  
 
1A- IC50  15.1 nM   13A- IC50 0.97 nM 
 
 
74- IC50 69.2 nM   NBMPR- IC50 8.51 nM 
 
 
 
NBMPR66- IC50 2.75 nM 
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Flavonoid45- IC50 101.9 ?M  Flavonoid100- IC50 0.13 ?M 
 
 
NBMPR6- IC50 7,413 ?M  NBMPR118- IC50 0.43 ?M 
 
Compound292- IC50 30.0 ?M 
Figure 2-12. Inactive set for hENT1 “combined” pharmacophore 
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Figure 2-13. “Combined” pharmacophore hypothesis with active compound 13A 
overlaid 
 
Note:  Light blue spheres indicate hydrogen bond donor, red spheres are hydrogen bond 
acceptors, orange rings are aromatic rings, and the green sphere represents a hydrophobic 
interaction.  
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Table 2-3. “Combined” pharmacophore CoMFA and CoMSIA PLS statistics 
 
PLS Statistics CoMFA CoMSIA  
q2 (LOO) 0.474 0.482 
r2 0.687 0.852 
S 0.654 0.456 
F 160.67 207.81 
PLS components 3 6 
Number of compounds used for model 224 223 
Number of outliers 4 5 
Number of compounds in external test set 24 24 
Steric descriptor contribution 0.533 0.140 
Electrostatic descriptor contribution 0.467 0.303 
Hydrophobic descriptor contribution n/a 0.186 
H-bond donor descriptor contribution n/a 0.150 
H-bond acceptor descriptor contribution n/a 0.220 
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As such the NBMPR and dipyridamole models were tested in their ability to pick 
active compounds from the database of known active molecules. The PHASE application 
was used to calculate conformations of the compounds in the database and tested them 
for fit in the pharmacophore. Neither pharmacophore could do so utilizing all seven 
points. However, when relaxed to four points, the dipyridamole model could identify all 
but one of the compounds and at three points, identified all of them. Even at three points, 
the NBMPR model could not identify the molecules. Table 2-4 shows the predicted and 
actual –Log IC50s of the compounds using the dipyridamole model. 
So while the NBMPR model identifies interactions important for binding of 
nucleosides and their analogues, it does not accurately reflect the interactions of small 
molecules. The bare minimum of three points required for the dipyridamole 
pharmacophore to identify hits, likely points to the key interactions required for affinity, 
while the other points potentially add to potency. Since, none of the small molecule hits 
were as potent as either dipyridamole or NBMPR, logic suggests that utilizing the 
pharmacophore to design analogues with functional groups that can occupy the three 
dimensional space indicated in the pharmacophore could lead to more potent compounds. 
 
hENT4 
 
Similar to hENT1, the flavonoid data were used to build pharmacophore, CoMFA 
and CoMSIA models (Figure 2-14 and Table 2-5). In addition the same model types 
were generated from dipyridmole analogue previously published biological data,1 of 
which the CoMFA and CoMSIA statistics are presented in Table 2-6. In addition, the 
residual plots (Figure 2-15 and Figure 2-16) depict the predictive ability of the models. 
The CoMFA model clearly demonstrated better predictive capability in regards to the test 
set than the CoMSIA model. 
As previously discussed, the flavonoids were not pursued for further study. Rather 
focus shifted to understanding the structure-activity relationship of the dipyridamole 
analogues via CoMFA and CoMSIA models. Even so, comparing the two models proves 
interesting. Both data sets produce models with very similar descriptor contributions, 
especially for the CoMSIA models. One could infer that the flavonoids potentially bind 
similarly to the dipyridamole analogues. 
 
hCNT3 
 
Using biological data from Wang et al.70 a pharmacophore model was generated 
for hCNT3. The study also published CoMFA and CoMSIA analysis, but while both 
methods are good at interpolating predicted activities of similar molecules, they do not do 
well at predicting the activity of novel molecular scaffolds. As mentioned before, it was 
desired to fine active compounds outside of the flavone chemical class. The 
pharmacophore model, which examined multiple conformations and does not rely on an 
alignment, served as a valuable tool for identifying new potentially active chemical 
classes. Figure 2-17 pictures the model chosen for the hCNT3 in silico screening. As  
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Table 2-4. PLS statistics for hENT4 flavonoid pharmacophore-aligned models 
 
PLS Statistics CoMFA CoMSIA 
q
2
 (LOO) 0.514 0.483 
r
2
 0.835 0.970 
S 0.214 0.097 
F 54.147 152.357 
PLS components 3 6 
No. of compounds used for model 36 35 
No. of Outliers 4 5 
No. of compounds in external test set 4 4 
Steric descriptor contribution 0.610 0.105 
Electrostatic descriptor contribution 0.390 0.295 
Hydrophobic descriptor contribution N/A 0.189 
H-bond donor descriptor contribution N/A 0.287 
H-bond acceptor descriptor contribution N/A 0.133 
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Figure 2-14. hENT4 flavonoid compounds used for pharmacophore design 
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Table 2-5. PLS statistics for hENT4 dipyridamole pharmacophore-aligned 
models  
 
PLS Statistics CoMFA CoMSIA 
q
2
 (LOO) 0.417 0.424 
r
2
 0.942 0.934 
S 0.216 0.233 
F 116.448 84.889 
PLS components 5 3 
Number. of compounds used for model 42 43 
Number of outliers 8 8 
Number of compounds in external test set 5 5 
Steric descriptor contribution 0.607 0.117 
Electrostatic descriptor contribution 0.393 0.191 
Hydrophobic descriptor contribution N/A 0.329 
H-bond donor descriptor contribution N/A 0.219 
H-bond acceptor descriptor contribution N/A 0.144 
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Table 2-6. hCNT3 pharmacophore statistics 
 
Statistic Value 
# Factors 1 
S 0.3826 
R2 0.3316 
F 28.8 
P 1.478x10-6 
Stability 0.4646 
RMSE 0.2485 
Q2 -1.0726 
Pearson-R 0.6964 
 
 
  
 
Figure 2-15. Residuals plot of CoMFA dipyridamole analogues 
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Figure 2-17. Flavone CNT3 pharmacophore 
 
Note:  Light blue spheres indicate hydrogen bond donor, red spheres are hydrogen bond 
acceptors, and orange rings are aromatic rings.  
  
Figure 2-16. Residuals plot CoMSIA dipyridamole analogues 
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biological screening was carried out at 10 ?M, a cut off of 5.5 [-Log(IC50)] was made, 
relegating much of the original data as “inactive”. The top three most active molecules 
were used in design of the pharmacophore (Figure 2-18). Unfortunately, the model was 
not statistically significant (Table 2-7). However, it served as a starting point for 
screening.  
The resulting pharmacophore was used to screen University of Cincinnati’s 
proprietary database of 360,000 molecules. Of the hits, 192 compounds were cherry-
picked for biological testing. Unfortunately, no significant hCNT3 hits were identified, 
but several hits were identified for the other transporters. (See Chapter 3 for screening 
results.)  
 
 
hCNT1 
 
Using the same published flavone data70, a pharmacophore was built for hCNT1 
(Figure 2-19). The three most active and three least active compounds were used to 
generate the model. The resulting model was used to search the same database of 
compounds. A 500 molecular weight cutoff was applied and the hits ranked according to 
predicted activity. Any flavones or nucleoside derivatives were excluded and the top 
ninety-six available compounds were purchased for biological testing.  
Two compounds demonstrated significant inhibition and their IC50 at 0.2 ?M [5-
3H] uridine were determined (see Chapter 3 for biological results). The original 
pharmacophore, due to a small initial active data set, had poor statistical significance. 
Using hit enrichment, i.e. adding the two hit compounds to the model, the new resulting 
model became significant, if still unstable. The resulting pharmacophore indicates a 
priority for hydrogen bond interactions rather than the aromatic rings seen in the original 
pharmacophore (Figure 2-20). This fits more in line with known substrates and the 
interactions necessary for nucleoside transport, but likely still is only a piece of the 
picture. Since the tested molecules showed a small degree of activity, it suggests that 
adding future analogue data to the model could further expand the SAR and  improve the 
model (Table 2-8). 
 
 
Summary and Conclusions 
 
Several different computer models were created in an effort to assist in the 
discovery of novel scaffolds for small molecule inhibition of nucleoside transporters. 
Four different sets of 3D-QSAR models were developed for hENT1. Among these, the 
dipyridamole analogue based models appeared most relevant for identifying biologically 
active inhibitors of hENT1, although both the dipyidamole and NBMPR CoMFA and 
CoMSIA were statistically significant. While the NBMPR models illuminated binding 
interactions for nucleosides and nucleoside analogues, it did a poor job of identifying 
non-nucleoside inhibitors. Both CoMSIA models appeared consistent with hydrogen 
bond-acceptor and hydrophobic contributions, but the dipyridamole model suggested an  
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    Flavone39      Flavone50 
       IC50 0.57 ± 0.2 ?M        IC50 0.68 ± 0.23 ?M 
 
 
Flavone84 
IC50 1.04 ± 0.60 ?M 
 
Figure 2-18. Flavones used for hCNT3 pharmacophore design 
.41 
Table 2-7. hCNT1 flavone pharmacophore statistics for original and hit-enriched models 
Model # Factors SD R2 F P Stability RMSE Q2 
Pearson 
R 
Original 1 0.2685 0.5958 22.1 0.000284 0.1235 0.1596 -5.2444 -0.6942 
Hit-enriched model 1 0.2309 0.7011 35.2 2.76E-05 -0.3809 0.0402 0.6039 0.8708 
 
 
 
 
 
 
 
 
 
 
Figure 2-19. hCNT1 flavone pharmacophore 
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Figure 2-20. Hit enriched hCNT1 pharmacophore 
 
 
 
Table 2-8. Dipyridamole pharmacophore search predictions 
 
ID Predicted –Log Activity Actual - Log Activity 
UC21 5.32 7.267606 
UC29* 5.61 6.769551 
UC33* 5.57 6.508638 
UC36* 5.49 5.835647 
UC60 5.18 5.522879 
UC63 5.17- 5.29** 5.471083 
UC65 5.70 6.161151 
UC70 5.37 6.853872 
UC86 5.27-5.29** 6.124939 
UC136 5.32-5.54** 5.595166 
UC137 5.18-5.32** 5.278189 
UC148 5.62-5.67 6.107905 
UC173 5.27 5.730487 
UC175 5.19 6.124939 
 
Note: *Compound appeared to have mixed activity. **Multiple ionization states were 
possible and scored separately. 
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increased contribution from hydrogen bond donors and a decrease in both steric and 
electrostatic contributions (Table 2-2). Considering NBMPR possesses a nitro group, and 
dipyridamole and its potent analogues lack such a highly polar and strong hydrogen bond 
acceptor group, this prediction correlates with the chemical functionality. As the position 
of the nitro substituent greatly effected potency,64 this suggested that steric interaction 
played a more important role in NBMPR analogue potency compared to the dipyridamole 
analogues, suggesting that this portion of the molecules may occupy the non-overlapping 
regions of the binding sites for hENT1.  
In addition, for identifying non-nucleoside molecules in future studies, the 
dipyridamole pharmacophore demonstrated the ability to identify active molecules as 
opposed to the NBMPR pharmacophore. Neither pharmacophore could identify known 
hits in a database when using all seven pharmacophore points, nor with six points 
matched. However, at five points the dipyridamole model identified UC29 and UC65 as 
hits and when search criteria were relaxed to four points, all hits were identified. 
However, their predictive values do not show a quantitative trend. Even at four points, 
the NBMPR model could not identify any of the UC compound hits. Table 2-9 contains 
the structures of the UC hENT1 hits.  
Without a transporter structure, one can only hypothesize in regards to binding, 
but the evidence suggests that small molecules bind more like dipyridamole than 
nucleoside analogues. Given that NBMPR and dipyridamole bind at overlapping sites, it 
is possible that other novel binding pockets exist, and that the small molecules may not 
all bind in the same manner. By its ability to select a wide variety of active molecules 
where the NBMPR model failed, the dipyridamole model appeared to support the theory 
of more than one binding location. When overlaying the compounds with the 
pharmacophore, not all hits occupied the same four pharmacophore points, further 
suggesting multiple binding modes. 
In order to further explore this idea, a series of compound derivatives would have 
to be made and tested, and common molecular scaffold pharmacophore-aligned CoMFA 
and CoMSIA models compared with combined models. As was done with the 
“combined” hENT1 models, if the compounds bind in the same binding pocket, the 
inclusive models would demonstrate better predictive ability and statistics than the 
individual models.  
Similarly, the 3D-QSAR models of hENT4, all of which were non-nucleoside 
based, correlated. This strongly suggested that the models identified the critical 
interactions required for potent inhibition of hENT4. In comparing the CoMSIA 
descriptors of the hENT1 dipyridamole model and the hENT4 model, it was noted that 
the distribution was very similar. However, hENT4 demonstrated a higher contribution of 
electrostatic interactions and less steric interactions in comparison to hENT1. 
Considering that hENT4 utilizes a proton, and at physiological pH transports primarily 
mono-amines,76 the shift in descriptor distribution correlated to known functionality, 
further supporting the validity of the models. 
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Table 2-9. hENT1 hit properties 
 
Structure ID 
IC50 
(μM) 
 
UC21 0.054 
 
UC29* 0.17 
 
UC33* 0.31 
 
UC36* 1.46 
 
UC60 3.00 
 
UC63 3.38 
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Table 2-9. Continued 
 
Structure ID 
IC50 
(μM) 
 
UC65 0.69 
 
UC70 0.14 
 
UC86 0.75 
 
UC136 2.54 
 
UC137 5.27 
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Table 2-9. Continued 
 
Structure ID 
IC50 
(μM) 
 
UC148 0.78 
 
UC173 1.86 
 
UC175 0.75 
 
Note: *Compound demonstrated mixed activity.
. 
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The contours for all of the presented CoMFA and CoMSIA models can be found 
in the Appendix (Figures A-1 through A-17). 
While the hCNT3 model proved wholly unsuccessful at discovering any hCNT3 
hits, it appeared to describe a general pharmacophore for equilibrative nucleoside 
transporter activity, resulting in thirteen hENT1 and three hENT4 hits (Chapter 3).  
In comparing the hCNT3 pharmacophore (Figure 2-17) with the flavonoid 
hENT1 pharmacophore (Figure 2-3), one notes a great deal of similarity. This likely 
pointed to the nature of flavonoid compounds and their broad spectrum of activity against 
many biological targets. Even so, the hCNT1 pharmacophore performed well, despite 
poor statistics, with a hit rate of 2.08%. The pyridone chemical class can serve as a 
starting point for further structure-activity elucidation relative to hCNT1. 
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CHAPTER 3.    BIOLOGICAL STUDIES 
Introduction 
A number of factors should be considered when selecting an assay system for 
screening chemical compounds for biological activity. First, one must understand that 
affinity does not always correlate to efficacy. For one, while cell biology has well 
characterized many pathways within cells, there remain mechanisms which are not 
understood or remain uncharacterized. In vitro chemical or enzyme assays are low in 
cost, but do not take into consideration the “cellular veil” i.e. the complex interactions 
and interdependence of inter- and intracellular signaling. Whole cell assays provide a 
means to test direct interaction with the cell, but do not address metabolism or biological 
distribution. Animal models can elucidate efficacy and proof of concept, but are 
expensive and many variables such as species variation, metabolism, bioavailability, and 
pharmacokinetics must be explored before utilizing animal models. 77 
As for the nucleoside transporters, a number of methods have been used in the 
literature over the years. Since most cell lines identified to date possess more than one 
type of transporter, they are not ideal for screening. Ward et al. established a transporter 
deficient pig kidney cell line (PK15NTD) and stably transfected it with cloned hENT1 
and hENT2.29 They, along with Wang et al. proceeded to express the remaining 
transporters, with the exception of hENT3, in PK15NTD cells.70 This allowed for each 
transporter to be screened individually. In some cases rat myoblast cells (H9c2)78 cells 
were used for testing of ENT2 function, but results were later cross-validated with 
PK15hENT2 cells.  
Experimental Methods 
Cell lines were grown and maintained in Eagle’s Minimum Essential Media 
(EMEM) with 10% fetal bovine serum and Geneticin G418 selector antibiotic at 5 mg/ml. 
A kill curve was run on the parental PK15NTD cell line and it necessitated up to 15 
mg/ml to achieve 100% cell mortality. Lower concentrations can be utilized with purer, 
more potent grades of G418. The G418 from KES Scientific, the supplier used for these 
studies, averaged only 70% potent.  
 
Also, to maintain expression of the transfected cells, they were reselected every 
60 days or a new vial of stock cells used for further experiments. Cells were plated at 
40,000 cells per well in Corning’s clear polystyrene forty-eight well plates and incubated 
at 37oC and 5% CO2 overnight. For screening, 10 ?M dilutions of compounds were 
prepared in either a sodium containing or sodium free buffer (Table 3-1) from 1mM 
stocks in dimethyl sulfoxide (DMSO).  For dose-response experiments, serial dilutions 
were made and tested. 
 
Screening and dose-response assays, except where indicated, were carried out 
technical triplicate. Compounds were tested using a radio-ligand uptake assay, utilizing  
. 
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Table 3-1. Uptake assay buffers 
 
Reagent for 
Sodium 
Buffer 
Final Concentration 
(mM) 
Reagent for 
Sodium Free 
Buffer 
Final Concentration 
(mM) 
NaCl 120 Choline Chloride 120 
Tris-HCl 20 Tris-HCl 20 
K2PO4 3 K2PO4 3 
Glucose 10 Glucose 10 
MgCl2 1 MgCl2 1 
CaCl2 1 CaCl2 1 
 
Note: pH adjusted with hydrochloric acid (HCl) or sodium hydroxide (NaOH) to 7.4 or 
6.0 for hENT4 
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previously established transgenic PK15NTD porcine cells expressing individual 
recombinant human (h)ENT29 or (h)CNT79 and/or H9c2 rat cells expressing native 
rENT2. For the rat cells, rENT1 was inhibited with 100 nM NBMPR prior to addition of 
analogues to avoid participation of the low level of ENT1 expressed by these cells. 
Decreased uptake of the 3H[5-] uridine indicated a “hit” and was confirmed by repeating 
the assay with serially diluted concentrations of the compounds to establish dose-
response curves. Positive controls were run with every plate. Table 3-2 lists the inhibitors 
and concentration used for each transporter. Figure 3-1 illustrates uptake assay 
procedure. 
 
 Readings were interpreted as percentage uptake relative to untreated cells. All 
chemicals used were of reagent grade and purchased from Sigma-Aldrich or Fisher 
Scientific. 
Results 
 
hCNT3 Pharmacophore Selections Screening 
 
10 mM stock solutions in DMSO were purchased from the University of 
Cincinnati. Working stock solutions of 1mM were prepared for all compounds in DMSO 
and all subsequent dilutions were in uptake assay buffer. All wells were run in triplicate. 
rENT2 was used and hits tested against hENT2. 
Figures 3-2 through 3-13 show the biological screening data. Some of the hits 
like UC9 for example, turned out to be false positives. Likely, the false positives which 
showed time dependent inhibition of uridine uptake were possible substrates and 
competed with the tritiated uridine for uptake. UC9, for example, appeared to markedly 
inhibit all tested ENTs. When retested using a twenty minute incubation period to 
confirm the hit, the apparent inhibition disappeared.  
Due to lack of hENT2 cells at the time screening began H9c2 cells expressing 
native rENT2 were used. Hits were cross screened against hENT2, but none of the hits 
maintained significant potency (Figure 3-14). Dose-response assays were then conducted 
on confirmed hits. Figure 3-15 and Figure 3-16 show the dose-response curves for 
hENT1 and hENT4 hits, respectively. 
Several compounds exhibited complex kinetics, suggesting perhaps that they are 
allosteric modulators and/or are mixed acting. Further kinetic studies would be required 
to define the mechanism of inhibition. 
The only hits of significant potency were those which hit hENT1, some of which 
were of sub-micromolar potency, and hENT4. While the hENT1 hits were of diverse 
chemical structures (Table 2-9), the hENT4 hits were all of the same chemical class, 
substituted imidazo[4,5f]quinolones (Figure 3-17). 
. 
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Table 3-2. Inhibitor controls used for uptake assays 
 
Transporter Inhibitor Concentration 
hENT1 NMBPR 100 nM 
hENT2/rENT2 Dipyridamole 1 ?M 
hENT4 WL30 1 ?M 
hCNT1 Phlorizin 250 ?M 
hCNT2 Phlorizin 250??M 
hCNT3 Phlorizin 250 ?M 
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Figure 3-1. Uptake assay procedure workflow 
 
Note: Total volume per/well was 500 μl. Volumes of test compounds, NBMPR, other 
standards, and tritiated uridine were adjusted accordingly.  
  
Equilibration 
• Rinse cells with sodium free buffer three times, discarding buffer 
each time. 
• Add 500 μl uptake buffer and equilibrate at room temperature for 
20 minutes. 
Inhibit 
• Remove buffer. (For H9c2 only, treat entire plate with 100nM 
NBMPR for 5 min.)  
• Add controls and dilutions of test compounds. 
• Incubate for 20 minutes. 
Uptake 
• Add 3H[5-] uridine, [0.4 ?M final concentration for equilibrative 
and 0.2 final concentration for concentrative transporters]. Mix. 
• Incubate 2 min. 
• Remove all liquid from plate and wash three times with ice-cold 
PBS pH 7.4. 
Lyse and 
count 
• Add 500 μl 5% Triton-X100 to each well. 
• Shake overnight and then aliquot 400 μl from each well into a 
separtate scintillation vial containtin 10 ml of scintillation fluid.  
• Vortex, shake overnight, and then read in a scintillation counter (3 
minute read/vial) 
. 
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Figure 3-2. UC1-UC15 screening results 
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Figure 3-3. UC16-UC30 screening results 
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Figure 3-4. UC31-UC45 screening results 
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Figure 3-5. UC46-UC60 screening results 
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Figure 3-6. UC61-UC75 screening results 
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Figure 3-7. UC76-UC90 screening results 
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Figure 3-8. UC91-UC105 screening results 
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Figure 3-9. UC121-UC135 screening results 
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Figure 3-10. UC136-UC150 screening results 
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Figure 3-11. UC152-UC165 screening results 
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Figure 3-12. UC166-UC185 screening results 
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Figure 3-13. UC186-UC192 screening results 
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Figure 3-14. Cross screen of rENT2 hits against hENT2 
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Figure 3-15. hENT1 dose response curves 
 
Note: IC50s*: (A) 54.4 nM (B) 173.2 nM (C) 309.2 nM (D) 156.4 nM (E) 1455 nM (F) 
65.5% Maximal Inhibition at 20 ?M (G) 3001 nM (H) 84.6% Maximal Inhibition at 20 
?M (I) 692.4 nM (J) 142.7 nM (K) 95.1% Maximal Inhibition at 10 ?M  (L) 747.8 nM 
(M) 2542 nM (N) 92.6% Maximal Inhibition at 15??M (O) 769.0 nM (P) 1681 nM (Q) 
745.1 nM 
*95% CI [M] (A) 1.455e-008 to 2.033e-007 (B) 2.235e-008 to 1.342e-006 (C) 1.979e-
007 to 4.829e-007 (D) 2.773e-008 to 8.818e-007 (E) 7.664e-007 to 2.764e-006 (F)  
2.332e-007 to 0.003096 (G) 1.121e-006 to 8.036e-006 (H) 2.208e-006 to 5.160e-006 (I) 
5.001e-007 to 9.586e-007 (J) 8.865e-008 to 2.298e-007 (K) 4.940e-007 to 1.793e-006 (L) 
4.591e-007 to 1.218e-006 (M) 1.290e-006 to 5.012e-006 (N) 2.209e-006 to 1.259e-005 
(O) 5.797e-007 to 1.020e-006 (P) 1.259e-006 to 2.245e-006 (Q) 5.267e-007 to 1.054e-
006 
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Figure 3-16. hENT4 dose response curves 
 
Note: IC50s*: (A) 3.76 ?M (B) 1.43 ?M (C) 24.2 ?M  
*95% CI [M] (A) 1.893e-006 to 6.363e-006 (B) 8.776e-007 to 2.318e-006 (C) 7.856e-
006 to 7.462e-005 
 
 
 
 
 
Figure 3-17. hENT4 hit structures 
  
  
%Inhibition hENT4 IC50 UC13
-9 -8 -7 -6 -5 -4
0
50
100
Log[13]
Pe
rc
en
t I
nh
ib
iti
on
   
%Inhibition hENT4 IC50 UC32
-8 -7 -6 -5 -4
-50
0
50
100
Log[32]
Pe
rc
en
t I
nh
ib
iti
on
 
       A      B 
 
%Inhibition hENT4 IC50 UC68
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Log[UC68]
Pe
rc
en
t I
nh
ib
iti
on
 
C 
. 
69 
hCNT1 Pharmacophore Selections Screening 
 
From the virtual screening of the hCNT1 pharmacophore (referred to as B set), 96 
compounds were tested for biological activity. All compounds were tested in triplicate 
and hits confirmed with dose response assays. A “hit” was defined as at least 75% 
inhibition at 10 ?M. The screening results are depicted in Figures 3-18 through 3-22.  
Using the 75% inhibition cut-off, only two molecules met the requirement for 
activity. Both 58B and 82B showed selectivity for hCNT1. Their IC50s were calculated 
using a dose response assay Figure 3-23. 
Both 58B and 82B belong to the same pyridone chemical class (Figure 3-24), 
supporting the supposition that derivatives can be used to explore the structure-activity 
relationship and build a larger database of molecules with hCNT1 activity, thus 
improving the ability of the pharmacophore model to predict activity. 
 
Vibrio Cholerae Selections Screening 
 
To compare the efficacy of the homology model to the published crystal structure, 
96 compounds drug-like were selected for biological testing against the CNT 
transporters. Figures 3-25 through 3-28 show the biological screening data. 
No compounds were selected for dose dependent assays, as none showed greater 
than 75% inhibition. V92 appeared to be the strongest hit, and only inhibited CNT1 by 
73%. As this was not a human transporter, the lack of hits served as confirmation of 
species selectivity and that any hits found with the homology model were not likely due 
to the similarity in vcCNTs and hCNTs. 
 
hCNT1 Homology Model Selections Screening 
 
One hundred seventy-seven molecules were selected for biological testing and 
each was tested in triplicate wells and against all of the concentrative transporters using 
the same procedures previously described. Figures 3-29 through 3-34 show the 
biological screening data. 
Summary and Conclusion 
The CNT3 pharmacophore failed to identify hCNT3 potent compounds. 
Reexamination of some of the compounds used to build the model indicated that they 
were likely competitive substrates rather than inhibitors. This supposition was supported 
by measuring uptake inhibition of some of the hits at more than one time point. UC9, for 
example, showed significant inhibition of all equilibrative transporters during initial 
screening (Figure 3-2) Noting that the first few screens were done with the 15min. pre-
incubation of the test compounds and then hits were repeated at 20min time points, all  
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Figure 3-18. B1-19 screening results 
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Figure 3-19. 20B-38B screening results 
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Figure 3-20. 39B-57B screening results 
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Figure 3-21. 58B-76B screening results 
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Figure 3-22. 77B-96B screening results 
 
 
 
 
 
 
 
 
 
 
 
Note: IC50s*: (A) 86.2% Maximal Inhibition at 50 ?M (B) 60.4 Maximal Inhibition at 30 
?M. Interpolated IC50s (A) 12.9 ?M (B) 16.9 ?M  
*95% CI [M] (A) 5.833e-006 to 2.855e-005 (B) 3.745e-006 to 7.623e-005 
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Figure 3-23. Dose response curves for hCNT1 hits 
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Figure 3-24. hCNT1 hit structures 
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Figure 3-25. V1-V24 screening results 
 
Note: The stocks of V5 and V6 intermixed during shipping of the 96-well plate. As no 
significant inhibition was noted, V5 and V6 were not reordered for separate testing. 
Given that there appeared to be potential agonism or activation of the CNT1 transporter, 
future studies might want to retest separately for confirmation. 
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Figure 3-26. V25-V48 screening results 
 
 
 
10 ?M Screen: Percent Activity
25
0 u
M 
Ph
lor
izi
ne V4
9
V5
0
V5
1
V5
2
V5
3
V5
4
V5
5
V5
6
V5
7
V5
8
V5
9
V6
0
V6
1
V6
2
V6
3
V6
4
V6
5
V6
6
V6
7
V6
8
V7
0
V7
1
V7
2
0
50
100
150
200
hCNT1
hCNT2
hCNT3
Pe
rc
en
t A
ct
iv
ity
 
Figure 3-27. V49-V72 screening results 
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Figure 3-28. V73-V96 screening results 
 
 
 
 
Figure 3-29. Homology model set 1-30 screening results 
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Figure 3-30. Homology model set 31-60 screening results 
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Figure 3-31. Homology model set 61-90 screening results 
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Figure 3-32. Homology model set 91-120 screening results 
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Figure 3-33. Homology model set 121-150 screening results 
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Figure 3-34. Homology model set 151-177 screening results* 
 
Note*: Compounds HM173-177 have not yet been tested against hCNT2  
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inhibitory activity disappeared for UC9, and a few others tested. Further kinetic studies, 
such as examining a time course of range of test compound concentrations at a range of 
concentrations of tritiated uridine to determine Kis and type of inhibitions (i.e. 
competitive, non-competitive, etc) and determine if the compound are capable on 
displacing standard inhibitors should be conducted to better understand the mechanisms 
of inhibition. 
Thus, while the model included pharmacophore elements for nucleoside 
transporter affinity, it lacked the interactions required for optimal inhibition. As hENT1 
was the most easily inhibited of all the transporters, and they all share similarity in their 
substrates, it was not a surprise that several hENT1 hits were identified. 
Of all the hits, UC21 proved most potent, possibly due to the trimethoxy 
substitution pattern, which has proven to increase activity in dilazep analogues as well as 
the flavonoids. All the compounds fall in polar surface area and molecular weight ranges 
for optimization for CNS penetration (Table 3-3). The diverse structures provide an 
excellent starting point for non-nucleoside potent and selective hENT1 inhibitors as well 
as potential allosteric modulators. If analogues of hENT4 hits are tested they could serve 
to expand the structure-activity relationship of non-nucleoside inhibitors of hENT4. All 
of the compounds require testing for toxicity before further studies are carried out. In 
addition a panel should be run to confirm selective potency against the desired target and 
that important enzymes are not inhibited. The drugs listed in Table 1-3 show it is not 
uncommon for cross reactivity. While cross reactivity does not always rule out a lead 
compound, it can help to know what sort of side effects and reactions to look for. 
In comparing the hCNT1 pharmacophore results and the homology model, they 
both performed similarly. The pharmacophore hits were not quite as potent, but identified 
two, whereas the homology model only produced one moderately potent hit. If the 75% 
inhibition cut off at 10 ?M is relaxed to 50% inhibition, then a number of hits emerge for 
both models. 
In fact, with the 50% inhibition cut-off, fourteen compounds inhibited hCNT2 at 
least 50% at 10 ?M. Only five hit hCNT1, with one hCNT3 hit. Whether this means the 
model is not truly selective or that hCNT1 and hCNT2 simply share a common 
pharmacophore remains to be seen. Testing of analogues related to the hits could 
elucidate the difference. Of particular interest are the compounds that appeared to show a 
2- to 4-fold increase in uptake relative to control. While the aim of this study was to 
identify inhibitors, these results should be noted and explored for future studies (Figure 
3-35 and 3-36). 
When looking at the 50% inhibition cut-off, the homology model out-performed 
the hCNT1 pharmacophore model with fourteen hCNT1 hits. The hCNT1 hit, HM50 had 
a calculated IC50 of 9.5 ?M (Figure 3-37), lower than either of the pharmacophore hits. 
While HM152 appeared to possess activity in the initial screen, it did not show a dose 
dependent relationship when retested. In addition there were seven weak hCNT2 hits and 
nine weak hCNT3 hits. This indicated that the model showed selectivity toward hCNT1. 
However, HM50 proved to be only slightly more potent than 52B and 82B. While 52B 
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and 82B are pyridone structures, HM50 is a purine analogue (Figure 3-38). It is possible 
that exploring the pyridone derivatives may elucidate the pharmacophore elements that 
differentiate a substrate from an inhibitor. While other purine analogues were selected by 
the model, none showed significant activity in comparison to HM50.  
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Table 3-3. hENT1 hit properties 
 
Structure ID IC50 (μM) MW #HBD #HBA tPSA 
 
UC21 0.054 381.43 1 7 73.67 
 
UC29* 0.17 533.67 2 6 98.25 
 
UC33* 0.31 464.590830 1 4 64.68 
 
UC36* 1.46 431.54 2 4 79.79 
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Table 3-3. Continued 
 
Structure ID IC50 (μM) MW #HBD #HBA tPSA 
 
UC60 3.0 434.52 1 6 69.15 
 
UC63 3.38 386.79 1 5 100.9 
 
UC65 0.69 427.45 2 6 95.48 
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Table 3-3. Continued 
 
Structure ID IC50 (μM) MW #HBD #HBA tPSA 
 
UC70 0.14 288.74 1 5 42.89 
 
UC86 0.75 312.37 2 2 46.69 
 
UC136 2.54 600.63 1 7 84.86 
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Table 3-3. Continued 
 
Structure ID IC50 (μM) MW #HBD #HBA tPSA 
 
UC137 5.27 309.346120 1 4 45.98 
 
UC148 0.78 469.49 2 5 81.18 
 
UC173 1.86 330.36 2 2 44.62 
 
UC175 0.75 387.38953 1 6 64.44 
 
Note: *Compound demonstrated mixed activity.
. 
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Figure 3-35. hCNT1 pharmacophore model screening results 
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Figure 3-36. Homology model compounds screening results 
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Figure 3-37. Dose dependent curve for HM50 
 
Note: 83.1% Maximal Inhibition at 20 ?M. Interpolated IC50 =9.05 ?M, 95% CI= 
3.265e-006 to 2.506e-005 
 
 
 
 
  
Figure 3-38. HM50 structure 
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CHAPTER 4.    CHEMISTRY 
Methods 
Thin-layer chromatography (TLC) was conducted on silica gel plates (Analtech) 
and compounds were visualized by UV light (254 and 365 nm). 1D NMR spectra were 
recorded on a Varian Inova 300, 400, or 500 MHz NMR instrument, as indicated in each 
spectra in the Appendix, and by using dimethyl sulfoxide-d6 solvent. Flash column 
chromatography was performed on Fisher silica gel (170-400 mesh). Mass spectra were 
obtained on a Bruker-HP ESQUIRE ion trap LC/MS-(n) system. All solvents and 
reagents were purchased from Aldrich or other major chemical companies and used 
without further purification.  
Experimental 
 
Nucleoside Analogues 
 
When the project began, it started with the intent of expanding the SAR with 
regards to the 7-position of the tetrahydroisoquinoline derivatives of NBMPR identified 
in prior work as potent hENT1 inhibitors.80 The work was begun utilizing the published 
procedure shown in Scheme 4-1. 
Several compounds were made following the original procedure. Later, to 
improve yields, the CaCO3 was replaced with K2CO3 and then 18-crown-6 was added in 
catalytic amount to improve the solubility of the base in the ethanol. Given that the 6-
chloropurine riboside was readily available, and the amines were of varying cost, it was 
then used in excess. This route, while acceptable, made purification more complicated as 
the product and the riboside generally shared very similar solubility properties. Care had 
to be taken during the reaction not to overheat above 85oC. When this happened, the heat 
degraded the sugar, drastically dropping yields. For similar reasons, efforts at a 
microwave reaction scheme also did poorly. 
 
 
 
Scheme 4-1. General procedure for constrained NMBPR tetrahydroisoquinoline 
derivative synthesis 
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Due to the highly polar nature of the compounds, they tended to separate poorly 
with flash chromatography. When possible, recrystallization was the primary means of 
purification. Mass spectra and NMR spectra can be found for all synthesized compounds 
in the Appendix (Figures A-18 through A-48). 
 
 
Original Method 
 
 Structures of synthesized compounds can be found in Figures 4-1 and 4-2.  
 
1) (2R,3R,4S,5R)-2-(6-(6-chloro-3,4-dihydroisoquinolin-2(1H)-yl)-9H-purin-9-
yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (HCPN01) 
 
0.88 mmol 6-chloro-1,2,3,4-tetrahydroisoquinoline was added to a round bottom 
flask with 0.35 mmol 6-chloropurine riboside, and 0.70 mmol CaCO3 refluxed in ethanol 
for 24 hours. It was then purified by flash chromatography using 9:1 ethyl acetate: 
methanol. Product was recrystallized from methanol. MS (ESI) m/z 418 (M + H)+, 440 
(M + Na)+; C19H20ClN504; 1H NMR (DMSO-d6) 2.95 (t, J= 6 Hz, 2H), 3.55 (m, 1H), 3.66 
(m, 1H), 3.95 (m, 1H), 4.15 (t, 4Hz, 1H), 4.49 (broad s, overlapping 4.57, s, 3H), (broad 
overlapping peaks at 5.20, 5.31, 5.42 (s, 4H), 5.94 (d, J= 6Hz, 1H), 7.26 (m, 3H), 8.29 (s, 
1H), 8.46 (s, 1H), Yield 18.8%. 
 
 
Modified Methods 
 
2) 2-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-
9H-purin-6-yl)-1,2,3,4-tetrahydroisoquinoline-5-carbonitrile (HCPN05) 
 
1.52 mmol 6-chloropurine riboside was added to a round bottom flask with 1.26 
mmol 1,2,3,4-tetrahydroisoquinoline-5-carbonitrile, and 1.52 mmol CaCO3 refluxed in 
ethanol for 24 hours. Product was poorly soluble in ethanol and precipitated out. It was 
then purified by flash chromatography using ethyl acetate resulting in a white chrystalline 
solid. MS (ESI) m/ 409 (M + H)+, 431 (M + Na)+; C20H20N604; 1H NMR (DMSO-d6) ? 
3.08 (t, J= 5.5 Hz, 2H), 3.56 (m, 2H), 3.66 (m, 1H), 3.96 (d, J= 3.5 Hz, 1H), 4.15, (m, 
1H), 4.57 (m, 2H), 5.18 (d, J= 4.5 Hz, 1H), 5.28 (t, J=6 Hz, 1H), 5.37 (broad, s, 3-OH) 
5.45 (d, J= 6.5 Hz, 1H), 5.94 (d, J= 6 Hz, 1H), 7.42 (t, J= 8 Hz, 1H), 7.65 (d, J=7.5 Hz, 
1H), 7.71 (d, J= 8 Hz, 1H), 8.31 (s, 1H), 8.49 (s, 1H) Yield 7.7% . 
 
3) (2R,3R,4S,5R)-2-(6-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-9H-purin-9-
yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (HCPN09) 
 
1.13 mmol 6-chloropurine riboside was added to a round bottom flask with 0.943 
mmol 7-bromo-1,2,3,4-tetrahydroisoquinoline, and 1.13 mmol K2CO3 refluxed in ethanol 
for 24 hours. Reaction was cooled on ice to precipitate product.  Filtrate was rinsed with 
deionized water to remove the K2CO3 and dried. Then it was washed with methanol and 
dissolved in a small volume of ethyl acetate and recrystallized at 4oC. The TLC showed 
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one clean spot. MS (ESI) m/z  463 (M + H)+; C19H20BrN504; 1H NMR (DMSO-d6) ? 2.98 
(t, J= 6 Hz, 2H), 3.34 (d, J= 1.5Hz, 2H), 3.85 (m, 2H), 4.20 (d, J= 2.7Hz, 1H), 4.35 (m, 
1H), 4.51 (broad, s 1–OH), 4.77 (t, J= 6.3 Hz, 1H), 4.9 (m, 1H),  5.36 (broad, s 2–OH) 
6.0 (d, 6.3Hz, 1H), 7.14 (d, J= 8.1 Hz, 1H), 7.34, (m, 1H), 7.44 (s, 1H), 8.29 (d, J= 4.5 
Hz, 2H) Yield 24.5% . 
 
4) (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(2-methyl-5,6-dihydropyrido[3,4-
d]pyrimidin-7(8H)-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol (HCPN22) 
 
0.80 mmol 6-chloropurine riboside was added to a round bottom flask with 0.67 
mmol 2-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, and 1.60 mmol K2CO3 
refluxed in dry tetrahydrofuran for 24 hours. Riboside and K2CO3 were filtered from 
reaction mixture and then the solvent removed by rotovap. The crude product was 
allowed to dry overnight and then recrystallized in methanol. MS (ESI) m/z 397.9 (M )- 
422 (M+Na)+; C18H21N704; 1H NMR (DMSO-d6) ? 2.55 (s, 3H), 2.99 (t, J= 5.7 Hz, 2H), 
3.25 (m, 1H), 3.55 (m, 1H), 3.57 (m, 1H), 3.96 (m, 1H), 4.15 (m, 1H), 4.56 (m 3H), 5.19 
(d, J= 4.8 Hz, 1H), 5.26 (m, 2H), 5.46 (d, J= 6 Hz, 1H), 5.93 (d, J= 6 Hz, 1H), 8.32 (s, 
1H), 8.49 (s, 1H), 8.61 (s, 1H), Yield 20.9%. 
 
5) (2R,3R,4S,5R)-2-(6-(2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-9H-
purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (HCPN29) 
 
1.17 mmol 6-chloropurine riboside was added to a round bottom flask with 0.975 
mmol 2-chloro-5,6,7,8 tetrahydro-1,6-naphthyridine HCl salt, and 4.88 mmol K2CO3 
refluxed in 50:50 THF: ethanol for 24 hours. Riboside and K2CO3 were filtered from 
reaction mixture and then the solvent removed by rotovap. The crude product was 
allowed to dry overnight and then recrystallized in methanol. MS (ESI) m/z  (M+Na)+; 
C18H19ClN604; 1H NMR (DMSO-d6) ? 3.10 (t, J= 5.7 Hz, 2H), 3.77 (m, 1H), 3.88 (m, 
1H), 4.17 (d, J= 2.7 Hz, 1H), 4.33 (m, 1H), 4.66 (m, 3H), 4.75 (t, J= 5.4 Hz, 2H), 5.42 
(broad, s, 3H), 5.99 (d, J= 5.1 Hz, 1H), 7.34 (d, J= 8.1 Hz, 1H), 7.73 (d, J= 8.1 Hz, 1H), 
8.30 (s, 1H), 8.31 (s, 1H) Yield 9.5%. 
 
6) (2R,3R,4S,5R)-2-(6-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-9H-purin-9-yl)-5-
(hydroxymethyl)tetrahydrofuran-3,4-diol (HCPN30) 
 
1.24 mmol 6-chloropurine riboside was added to a round bottom flask with 1.03 
mmol 5,6,7,8-tetrahydro-1,6-naphthyridine HCl salt, and 5.15 mmol K2CO3 refluxed in 
50:50 THF: ethanol for 24 hours. Riboside and K2CO3 were filtered from reaction 
mixture and then the solvent removed by rotovap. The crude product was allowed to dry 
overnight and then recrystallized in methanol. MS (ESI) m/z 385 (M+H)+,407 (M+Na)+; 
C18H20N604; 1H NMR (DMSO-d6) ??3.0 (t, J= 6.3Hz, 2H), 3.24 (s, 1H), 3.64 (m, 3H), 
3.95 (m, 1H), 4.15 (t, 3.6Hz, 1H), 4.57 (t, J= 5.4 Hz, 3H), 5.35 (broad, s, 3H), 5.93 (d, J= 
6 Hz, 1H), 7.24 (m, 1H), 7.69 (m, 1H), 8.29 (s, 1H), 8.38 (d, J= 3.6 Hz, 1H), 8.46 (s, 1H) 
Yield 12.4%. 
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7) (2R,3R,4S,5R)-2-(6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-9H-purin-9-yl)-5-
(hydroxymethyl)tetrahydrofuran-3,4-diol (HCPN34) 
 
0.95 mmol 6-chloropurine riboside was added to a round bottom flask with 0.79 
mmol octahydropyrrolo[1,2-a]pyrazine, and 1.58 mmol K2CO3 refluxed in THF for 24 
hours. Riboside and K2CO3 were filtered from reaction mixture and then the solvent 
removed by rotovap. The crude product was allowed to dry overnight and then 
recrystallized in methanol. MS (ESI) m/z 399 (M+Na)+ ; C17H24N604; 1H NMR (DMSO-
d6) ? 1.41 (m, 1H), 1.70 (m, 2H), 1.83 (m, 2H), 1.93 (m, 2H), 2.33 (s, 1H), 2.78 (s, 1H),  
2.81 (s broad, 1H), 3.03 (m, 3H), 3.11 (s, 1H), 3.54 (m, 2H), 3.95 (m, 1H), 4.15 (m, 1H), 
4.57 (m, 1H), 5.19 (d, J= 4.8Hz, 1H), 5.33 (m, 1H), 5.46 (d, J= 6 Hz, 1H), 5.91 (d, J= 6 
Hz, 1H), 8.25 (s, 1H), 8.42 (s, 1H), Yield 2%. 
 
8) (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(6-methoxy-3,4-dihydroisoquinolin-
2(1H)-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol (HCPN58)—not tested 
 
1.84 mmol 6-chloropurine riboside was added to a microwave tube with 1.53 
mmol 6-methoxy-1,2,3,4-tetrahydroisoquinoline, and 3.07 mmol K2CO3 in ethanol for 24 
hours. Riboside and K2CO3 were filtered from reaction mixture and then the solvent 
removed by rotovap. The crude product was allowed to dry overnight and then 
recrystallized in methanol. MS (ESI) m/z 436. 2 (M+Na)+; C20H23N505; 1H NMR 
(DMSO-d6) ??2.91 (t, J= 5.6 Hz, 2H), 3.56 (m, 3H), 3.67 (m, 2H), 3.70 (s, 1H), 3.96 (m, 
1H), 4.14 (m, 1H), 4.45 (broad, s, ~H), 4.57 (broad s, 1H), 5.18 (broad, s, 2H), 5.33 
(broad, s, 1H), 5.46 (broad,s, 1H), 5.92 (d, J= 6 Hz, 1H), 6.77 (m, 2H), 7.16 (d, J= 8.4Hz, 
1H), 8.28 (s, 1H), 8.44 (s, 1H)  Yield 56%. 
 
9) (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(5-(trifluoromethyl)-3,4-
dihydroisoquinolin-2(1H)-yl)-9H-purin-9-yl)tetrahydrofuran-3,4-diol 
(HCPN69)—not tested 
 
0.51 mmol 6-chloropurine riboside was added to a microwave tube with 0.42 
mmol 5-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride salt, 0.92 mmol 
K2CO3 and a catalytic amount of 18-crown-6  in ethanol for 24 hours. Riboside and 
K2CO3 were filtered from reaction mixture and then the solvent removed by rotovap. The 
crude product was allowed to dry overnight and then recrystallized in methanol. MS 
(ESI) m/z  (M+Na)+; C20H20F3N504; 1H NMR (DMSO-d6) ? 3.05 (t, J= 6 Hz, 2H), 3.55 
(m, 2H), 3.67 (m, 2H), 3.95 (m, 1H), 4.14 (m, 1H), 4.55 (t, J= 5.2 Hz, 2H), 5.21 (broad, s, 
2H), 5.24 (broad, s, 2H), 5.93 (t, J= 4.8 Hz, 1H), 7.40 (t, J= 7.6 Hz, 1H), 7.50 (d, J= 7.6 
Hz, 1H), 7.55 (d, J= 7.6 Hz, 1H), 8.32 (s, 1H), 8.47 (s, 1H), Yield 41.9%. 
 
10) 2-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-
9H-purin-6-yl)-1,2,3,4-tetrahydroisoquinoline-5-carboxylate (HCPN78)—
not tested 
 
0.87 mmol 6-chloropurine riboside was added to a microwave tube with 1.2 mmol 
1,2,3,4-tetrahydroisoquinoline-5-carboxylate hydrochloride salt, and 4.2 mmol K2CO3 in 
. 
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ethanol for 24 hours. Riboside and K2CO3 were filtered from reaction mixture and then 
the solvent removed by rotovap. The crude product was allowed to dry overnight and 
then recrystallized in methanol. MS (ESI) m/z  (M+Na)+; C20H21N506; 1H NMR (DMSO-
d6) ? 2.32 (s, 1H), 3.21 (m, 4H), 3.54 (m, 3H), 3.95 (m, 1H), 4.15 (m, 1H), 4.56 (m, 1H), 
5.21 (m, 2H), 5.35 (m, 2H), 5.51 (m, 1H), 5.92 (d, J= 5.84Hz, 1H), 7.21 (m, 1H), 7.47 
(m, 1H), 8.21 (s, 1H), 8.44 (s, 1H) Yield 11.5%. 
 
 
Pyridone Analogues 
 
Literature searches provided a number of established methods for synthesizing 
pyridones, depending on the substitution pattern. The first method used (Scheme 4-2) 
involved reaction of a substituted diketone with 2-cyanoacetimide with an acidic aqueous 
workup. While Pyr2 (Figure 4-3) was successfully produced with this method, 
depending on R1 and R2 and the electron donating or withdrawing capacity of those 
substituents, more than one structural isomer could result. Two other compounds 
attempted with this method resulted in what was suspected to be a flavone-like bicyclic 
structure instead of the desired products. Even for the compounds synthesized in this 
manner, it was required to synthesize the diketones. Thus, the synthetic scheme resulted 
in several purification steps, thereby decreasing yields to less than 20%. 
To synthesize the diketones, 2’-hydroxyacetophenone was reacted with an 
aromatic acid chloride, followed by Baeyer-Villiger rearrangement.81 Heteroaromatic 
compounds in particular proved less reactive. 
 
An alternate one-pot synthesis method was adopted after further search into the 
literature (Scheme 4-3).82 The initial test reaction, which was conducted neat, worked, 
but yield was poor and required hours rather than the mere 10-15 minutes reported in the 
reference. Dissolving all reactants in propanol and refluxing at 110oC greatly improved 
the reaction’s efficiency, but heteroaromatics remained less reactive in comparison to 
aromatic carbocyclics. 
 
 
 
 
 
 
 
 
 
Note: Reagents and conditions: (a) toluene, DBU, reflux, 95oC 
 
 
 
Scheme 4-2. Synthetic procedure for diketone and 2-cyanoacetimed synthesis 
of substituted pyridones 
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Figure 4-1. Synthesized and tested nucleoside analogues 
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Figure 4-2. Synthesized and untested nucleoside analogues 
 
 
 
 
 
Figure 4-3. Synthesized and tested pyridones 
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Scheme 4-3. One-pot synthesis of pyridones 
 
Note: Reagents and conditions: propanol, 110oC, 24 hrs. 
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Method One 
 
First 2-hydroxyacetophenone was reacted in a 1:1 molar ratio with the appropriate 
aryl acid chloride at room temperature overnight or until reaction was judged by TLC to 
be complete.   
 
11) 6'-(2-hydroxyphenyl)-2'-oxo-1',2'-dihydro-[3,4'-bipyridine]-3'-carbonitrile 
(Pyr2) 
 
10 mmol of 2-hydroxyacetophenone was reacted with 1.44 mmol of nicotinic 
carbonyl chloride HCl salt at room temperature overnight in 25ml of pyridine. Reaction 
was worked up by adding water and then adjusting the pH to approximately 4. The 
precipitated diketone intermediate, bright yellow crystals, was filtered and dried 
overnight (14% yield). Then 0.5 mmol reaction intermediate was reacted with 0.5mmol 
2-cyanoacetamide in toluene and 0.025 mmol DBU (1,8-Diazabicycloundec-7-ene). 
21mg of product obtained through recrystallization in methanol. MS (ESI) m/z  289 (M-
H)-; C17H11N302; 1H NMR (DMSO-d6) ?7.22 (s, 1H), 7.65 (m, 2H), 7.84 (m, 2H), 8.07 (d, 
J= 8 Hz, 1H), 8.52 (m, 1H), 8.79 (m, 1H), 9.33 (m, 1H), exchangeable protons not 
visible, (<1% yield). 
 
Method Two 
 
12) 4-(2-hydroxynaphthalen-1-yl)-6-(2-hydroxyphenyl)-2-oxo-1,2-
dihydropyridine-3-carbonitrile (Pyr3) 
 
5.8 mmol of 2-hydroxy-1-naphthaldehyde was reacted with 5.8 mmol 2′-
hydroxyacetophenone, 5.8 mmol of ethyl cyanoacetate and 5.8 mmol ammonium acetate 
in propanol and refluxed at110oC until 2-hydroxy-1-naphthaldehyde spot on TLC was 
judged to either be gone or reaction had ceased to progress further. Product was insoluble 
in propanol and precipitated out. Product was filtered, rinsed and then dried. MS (ESI) 
m/z 355 (M+H)+ ; C22H14N203; 1H NMR (DMSO-d6) ?7.01 (m, 3H), 7.4 (m, 1H), 7.58 (d, 
J= 8.8 Hz, 1H), 7.67 (t, J= 7.2 Hz,1H), 7.84 (m, 1H), 8.02 (d, J= 7.2 Hz, 1H), 8.14 (d, J= 
8 Hz, 2H), 8.25 (m, 3H),13.44* (s, 1H), Yield 24%. 
*Peak indicates pyridine tautomer. 
 
13) 6-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2-oxo-1,2-dihydropyridine-3-
carbonitrile (Pyr4) 
 
6.6 mmol of 3-nitrobenzaldehyde was reacted with 6.6 mmol 2′-
hydroxyacetophenone, 6.6 mmol of ethyl cyanoacetate and 6.6 mmol ammonium acetate 
in propanol and refluxed at110oC until 3-nitrobenzaldehyde spot on TLC was judged to 
either be gone or reaction had ceased to progress further. Propanol was evaporated and 
residue was washed with sodium bicarbonate. Product precipitated out of the aqueous 
solution was dried and washed with ethyl acetate and then recrystallized in acetonitrile at 
-20oC. MS (ESI) m/z   331.8 (M-H)-; C18H11N304; 1H NMR (DMSO-d6) ??6.65 (m, 1H), 
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6.67 (m, 1H), 6.85 (s, 1H), 7.1ff8 (m, 1H), 7.81 (t, J= 8Hz, 1H), 7.87 (m, 1H), 8.07 (m, 
1H), 8.32 (m, 1H), 8.40 (m, 1H),?Yield 80%. 
 
14) 6-(2-hydroxyphenyl)-2-oxo-4-(1H-pyrrol-2-yl)-1,2-dihydropyridine-3-
carbonitrile (Pyr6) 
 
1 mmol of 1H-pyrrole-2-carbaldehyde was reacted with 1 mmol 2′-
hydroxyacetophenone, 1 mmol of ethyl cyanoacetate and 1 mmol ammonium acetate in 
propanol and refluxed at110oC until 1H-pyrrole-2-carbaldehyde spot on TLC was judged 
to either be gone or reaction had ceased to progress further. Propanol was evaporated and 
residue was washed with sodium bicarbonate and ethylacetate. Organic phase was dried 
with magnesium sulfate and recrystallized at -20oC. MS (ESI) m/z   278 (M+H)+,  
C16H11N302; 1H NMR (DMSO-d6) ? 6.47 (m, 3H), 7.43 (overlapping m, 4H), 8.1 (slightly 
broad s, 3H- OH) 8.5* (s, 1H), N-H not visualized.  Yield <1% 
*Likely also in pyridine tautomer due to ppm shift being so far downfield. 
 
 
Results 
 
The nucleoside analogue synthesis procedure called for a 1:2.5:2 molar ratios for 
the 6-chloropurine riboside to the tetrahydroisoquinoline derivative and calcium 
carbonate in ethanol and refluxed at 85oC for 15 hours.  Due to limited amounts of the 
tetrahydroisoquinoline starting reagents, they were made the limiting reactant. However, 
it was later determined that this resulted in a very difficult separation and the ratios were 
eventually returned to the original procedure.  
Even with the tetrahydroisoquinoline derivatives as the excess reactant, in general 
the reaction resulted in poor yields under the proscribed conditions as CaCO3 was nearly 
insoluble. In addition, many of the tetrahydroisoquinoline starting materials were HCl 
salts, requiring far more base to produce the nucleophilic free base of the 
tetrahydroisoquinolines. K2CO3 was substituted for its improved solubility, and a 
catalytic amount of 18-crown-6 was found effective at solvating the potassium ion.83 
Depending on the electron donating or electron-withdrawing nature of the substitution on 
the tetrahydroisoquinolines and related reagents, the reactions often sometimes took 
longer 24 hours and rarely went to completion. However, poor solubility likely 
contributed the most to decreased yields. Some attempted reactions did not proceed, 
likely due to steric interactions. The same reactions were attempted in the microwave, but 
the ribose ring was very sensitive and tended to decompose, producing little to no 
product.  
Table 4-1 shows the biological activity of the synthesized compounds. In addition 
to the parent compound known in these studies as compound-4 (Figure 4-4), ten 
compounds were successfully made, seven of which were tested for biological activity 
(Figure 4-1). The project was halted before testing was conducted on the other 
compounds (Figure 4-3).  
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Table 4-1. Synthesized nucleoside derivative screening results 
 
Compound hENT1 IC50 (nM) 
HCPN01 40.98 
HCPN05 85.04 
HCPN09 53.77 
HCPN22 Inactive 
HCPN29 >1 uM 
HCPN30 >1 uM 
HCPN34 58.91 
  
 
 
 
Figure 4-4. Compound-4 structure 
 
Note:  Reported hENT1 IC50 0.45nM80 
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Exchanging the tetrahydroisoquinoline benzene ring system for heteroaromatic 
systems abolished activity, as did saturating the ring systems. HCPN01 and HCP09 
which showed the best activity against hENT1, both have halogens in place of the nitro 
group found in the parent compound. Although they retained activity, they were far less 
potent than the parent compound. As halogens can undergo dipole interactions, this could 
explain the retention of some activity, but clearly it was not optimal. As nothing else in 
the molecule changed, this demonstrated the importance of the 7-position nitro group for 
potency and the sharp line between moderate activity and potent inhibitor. This agreed 
with prior studies which showed that analogues showed decreased activity when the nitro 
groups was moved to other positions on the tetrahydroisoquinoline ring. Further, the 
nitrile group, which instead occupies the five-position may be able to partially interact 
with the transporter, but with decreased affinity. A compound with the nitrile in the same 
position would potentially retain activity as the nitrile group could participate in an 
electrostatic interaction, depending on the steric properties of the binding pocket. As 
such, synthesizing a molecule of that nature could further elucidate the interactions of 
inhibitor and transporter at that position. 
 
Figure 4-3 shows the synthesized pyridone analogues. As both lead compounds 
contained hydrogen bond acceptors in the four substituted position, it was hypothesized 
that it was required for activity. Indeed, compounds without a hydrogen bond acceptor 
had no activity (Figure 4-6). The pyrrole ring in Pyr 6 would be protonated at 
physiological pH and under assay conditions, and as such would not be a hydrogen bond 
acceptor, but rather a donor. Unfortunately none of the analogues showed as significant 
activity as the parent compounds and more would have to be synthesized to expand the 
structure activity relationship. 
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Figure 4-5. Pyridone screening results 
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CHAPTER 5.    BROAD INSTITUTE COLLABRATIVE STUDY 
Introduction 
Dr. Timothy Lewis and his group at the broad institute at Harvard synthesized a 
series of dilazep analogues to explore the structure-activity relationship in regards to 
ENT1 and ENT2 (submitted for publication). Prior work had identified hENT1 inhibitors 
dipyridamole and dilazep as novel potential agents for use in improving the efficacy of 
oncolytic herpes simplex virus-1 replication rate.52 In contrast to many chemotherapies 
currently used to treat cancer, oHSV1 only targets cancerous cells. Unfortunately oHSV1 
use in the clinic is limited by poor replication rate and spread to nearby cancerous cells. 
The discovery of the potential synergistic role of ENT1 and ENT2 inhibitors could 
increase the utility of this novel cancer treatment method.  
Methods 
 The compounds were screened in duplicate in the same manner as described in 
Chapter 3. Dose response assays of hits were conducted in triplicates and non-linear 
regression curves were calculated with least squares method in GraphPad Prism 5. 
Compounds that demonstrated significant and selective inhibition were explored 
further with dose dependent assays. 
Results 
Figures 5-1 through 5-3 show the biological screening data while Table 5-1 lists 
the IC50s of the biologically potent compounds. With the exception of M7, all the tested 
compounds showed similar screening results when tested against hENT2, although the 
trend showed the rENT2 perhaps proving slightly more sensitive to the more potent 
compounds (Figure 5-4). M7 had poor activity against both, so its deviation is not of 
significant importance. 
 
While dilazep (Figure 5-5) inhibited hENT1 and (r/h)ENT2, ENT2 exhibited 
over five hundred-fold less sensitivity. Although no potent ENT2 selective compound 
was identified, cell screening identified four compounds with increased potency against 
ENT2 and similar or increased potency against hENT1. 
 
Dilazep (Figure 5-5) and close analogues (Figure 5-6) proved to be potent 
hENT1 inhibitors (IC50 < 100 nM) with little or no activity against rENT2. Modification 
of the homopiperazine was tolerated with replacement using a piperazine, or methyl-
substitued piperazine ring. In addition the alkyl chains showed tolerance to length 
alteration with both one carbon longer and shorter retaining potency. Replacement of  
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10 ?M Screening of Dilazep Analouges
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Figure 5-1. 10 ?M screening of A1-E11 against hENT1 and rENT2 
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Figure 5-2. 10 ?M screening of E13-I23 against hENT1 and rENT2 
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10?M Screen of Dilazep Analogues
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Figure 5-3. 10 ?M screening of K1-O7 against hENT1 and rENT2 
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Table 5-1. Dilazep analogue IC50s 
 
Compound 
hENT1 IC50 [nM] 
(95% CI) 
rENT2 IC50 [nM] 
(95% CI) 
I5(M21) 
31.0 
(13.4-71.7) *** 
G23Dilazep 
17.5 
(9.4- 33.8) 
8795 
(2075-37280) 
I1 
66.1 
(35.7-122) 
1309 
(897.7-1909) 
I5 
93.9 
(27.9-315.7) *** 
I7 
802.6 
(503.4-1280) *** 
I9 
7136 
(1564-32.6 ?M) *** 
K3 
216.9 
(112.4-418.6) *** 
M13 
2.8 
(1.6-4.7) 
977 
(598-1690) 
M19 
4.6 
(2.5-8.6) *** 
M23 
17.7 
(12.8-25.7) 
1074 
(642.5-1796) 
O1 
3.2 
(1.7-6.2) 
1488 
(843.2-2625) 
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Uptake  inhibition comparison of rat and human ENT2
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Figure 5-4. Uptake inhibition comparison of rat and human ENT2 
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Figure 5-5. Dilazep structure 
 
 
 
 
Figure 5-6. Potent dilazep analogues 
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ester bonds with amides retained activity, but replacement with ether or heterocycle 
greatly diminished hENT1 activity was diminished. The 3,4,5-(OMe)3 substituted phenyl 
rings showed the best activity, but two of the groups are not required based on the 
activities of I7 and K3, in which only one methoxy is required for hENT1 activity. While 
one compound M13 demonstrated ENT2 activity just under 1 ?M, no potent, selective 
ENT2 inhibitor was identified (Table 5-1). Based on the results, it was concluded that the 
mechanism of improvement of oHSV1 replication efficiency when treated with dilazep 
involved ENT1 rather than ENT2. More mechanistic studies are required to elucidate the 
exact mechanism. The data have been submitted for publication. 
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CHAPTER 6.    CONCLUSION AND FUTURE STUDIES 
 
 
The collective results of this work highlight the difficulties faced in drug 
discovery when the structure of the target is not known. While fourteen hENT1 hits and 
three hENT4 hits were found serendipitously with the hCNT3 pharmacophore, the initial 
screen failed at finding any hCNT3 hits. Later, when the biological data used to build the 
pharmacophore were reviewed, it was determined that some of the compounds were 
potentially substrates or rapid reversible inhibitors, but as previously described, further 
kinetic studies  would be required to ascertain which. To confirm substrates, one method 
might involve tagging the test compound with a radio isotope and determining if it is 
taken into the cell. Several initial hits demonstrated the phenomenon of appearing potent, 
but upon retesting with a different incubation period, showed marked decrease or total 
lack of apparent inhibition. This highlights that with regards to molecular modeling, 
pinpointing that the key features between substrate and inhibitor are not particularly well 
defined. The failure of the screen shows the most significant limitation to molecular 
modeling with regards to 3D-QSAR methods in that models are only as good as the 
biological data used for analysis. 
Looking at the well characterized hENT1, with many known compounds that can 
inhibit it at a wide variety of concentrations, it is interesting to note the differences in the 
flavonoid models versus the NBMPR models or even the dipyridamole models. The 
highly potent dipyridamole and NMBPR analogues both yielded statistically significant, 
predictive models when aligned with a seven-point pharmacophore. However, the 
moderate potency flavonoids only produce a five-point pharmacophore. Taken with the 
ability of the dipyridamole model using four pharmacophore points to identify the UC 
compounds found to be biologically active, one could conjecture that a minimum of four 
pharmacophore points are required for activity, but not necessarily the same four points. 
The synthesized molecules, which were highly similar to the potent Compound-4 showed 
a marked decrease in activity, demonstrating that very small changes can sharply increase 
or decrease the potency of a potential inhibitor, and that while the transporters have a 
broad spectrum of compounds they transport, it is possible to optimize a compound to 
selectively and potently target a specific transporter. Even at their current potency, 
several of the synthesized compounds are well within pharmacologically relevant ranges. 
They could be tested against bacteria or for toxicity in cancer cell lines, as 
antimetabolites have been a proven efficacious route. 
While the other nucleoside transporters lack the compound diversity for a similar 
molecular modeling comparison, based on their functionality and over-lapping permeant 
selectivity one might hypothesis that for each transporter there is a nucleoside-based 
pharmacophore and at least one or more potential pharmacophores for non-nucleoside 
molecules. Further work to expand series of compounds for each of the transporters could 
serve to test that postulate. 
The hCNT1 screening proved to be most productive, especially given the limited 
size of the original data set. Likewise, the Vibrio cholera crystal structure allowed for the 
generation of a homology model that also successfully identified active compounds, 
. 
109 
albeit only one, HM50, of more than moderate micromolar potency. While screening of 
synthesized pyridones yielded little in the way of conclusive results, the synthesized 
molecules were few in number, and a much larger library is needed to expand the 
structure-activity relationship, especially in regards to differentiating substrate versus 
inhibitor pharmacophore points. While the original model indicated hydrogen bond donor 
and aromatic rings as important pharmacophore elements, the hit-enriched model 
suggested that hydrogen bond acceptors played a more important role, which the trend in 
the biological data seemed to support, but expansion of the data set is required to fully 
test this theory.  This is suggested as the focus of future work.  
In regards to the collaborative work, it resulted in some very promising 
compounds of nanomolar potency, even though the goal of producing an ENT2 selective 
compound was not met.  The identified compounds could potentially lead to an adjunct 
therapy for improving the efficacy of oHSV1 treatments. The blockade of the nucleoside 
transporters would prevent the cells from taking up nucleosides to replicate and allow the 
intercellular nucleosides to be used by oHSV1. This could potentially cause cell arrest, 
giving oHSV1 time to replicate enough to spread to nearby cancerous cells. 
 Of particularly interesting note, when looking at dilazep and comparing it to the 
most potent hENT1 inhibitor found in the initial UC compound screening the (UC21), 
one can see a similarity in structure. UC21 possesses fewer flexible bonds, but retains the 
tri-methoxy substitution pattern (Figure 6-1). Also similar to the dilazep analogues, 
UC21 concurs with the trend that a symmetrical molecule is not required for activity. 
Both the NBMPR and dipyridamole pharmacophores suggest that symmetry is not 
required, which provides another potential area of molecular modifications. 
It is possible that in some cases such as with hENT1 and hENT2, due to the 
similarity of the transporters, compounds with only minor changes to the same core 
structure may elucidate SAR for a series but fail to achieve selectivity as specific cores in 
and of themselves may be more selective toward a specific transporter. As mentioned 
before, hENT4 shares less similarity and utilizes alternative methods of functionality 
compared to hENT1 and hENT2. As such, it is interesting that selective and potent 
dipyridamole analogues were identified for both hENT170 and hENT4.1 Then again, 
dipyridamole is known to interact with other molecules and its nucleoside transporter 
activity was discovered after the fact. Dipyridamole is a phosphodiesterase 3 (PDE3) 
inhibitor, demonstrating that often compounds may achieve the desired biological 
response through interacting with more than one target in vivo.84  
 While the drug potentials are still far off on the horizon, exploring the roles of 
nucleoside transporters is crucial to understanding cellular signaling, transport, and the 
role they play both in normal cells and in diseased states. This study identified a number 
of compounds for which derivations can be used for that purpose. In addition, the hENT1 
models, in particular the dipyridamole pharmacophore model and the flavonoid hCNT1 
pharmacophore model can aid in identifying potential active compounds. 
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Figure 6-1. Dilazep and UC21 comparison 
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APPENDIX. SUPPLEMENTAL DATA 
Modeling Data 
  
hENT1 Models 
 
 
Flavonoid CoMFA Contours 
 
 
 
Figure A-1. Flavonoid CoMFA contours of hENT1  
 
Note: CoMFA color key. Steric: green- favored, yellow- disfavored; electrostatics: blue-
favored, red- disfavored.  
 
 
Dipyridamole CoMFA and CoMSIA Contours 
 
 
 
Figure A-2. hENT1 dipyridamole CoMFA contours 
 
Note: CoMFA color key. Steric: green- favored, yellow- disfavored; electrostatics: blue-
favored, red- disfavored. 
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Figure A-3. hENT1 dipyridamole CoMSIA electrostatic and steric contours 
 
Note: CoMSIA color key. Steric: green- favored, yellow- disfavored; electrostatic: blue- 
favored, red-disfavored 
 
 
 
 
 
Figure A-4. hENT1 dipyridamole CoMSIA hydrophobic contours 
 
Note: CoMSIA color key. Hydrophobic: yellow- favored, white- disfavored 
. 
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Figure A-5. hENT1 dipyridamole CoMSIA hydrogen bond donor and acceptor 
contours 
 
Note: CoMSIA color key. Hydrogen-bond donor: cyan- favored, purple- disfavored; 
Hydrogen-bond acceptor: magenta- favored, red- disfavored. 
 
 
NBMPR CoMFA and CoMSIA Contours 
 
 
 
Figure A-6. NBMPR CoMFA hENT1 contours 
 
Note: CoMFA color key. Steric: green- favored, yellow- disfavored; electrostatics: blue-
favored, red- disfavored. 
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Figure A-7. NBMPR hENT1 CoMSIA steric and electrostatic contours 
 
Note: CoMSIA color key. Steric: green- favored, yellow- disfavored; electrostatic: blue- 
favored, red-disfavored. 
 
 
 
 
 
Figure A-8. NBMPR hENT1 CoMSIA hydrophobic contours 
 
Note: CoMSIA color key. Hydrophobic: yellow- favored, white- disfavored. 
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Figure A-9. NBMPR hENT1 CoMSIA hydrogen bond donor and acceptor 
contours 
 
Note: CoMSIA color key. Hydrogen-bond donor: cyan- favored, purple- disfavored; 
hydrogen-bond acceptor: magenta- favored, red- disfavored. 
 
 
hENT4 Models 
 
hENT4 Dipyridamole Models 
 
 
 
Figure A-10. Dipyridamole hENT4 CoMFA contours 
 
Note: Color key. Steric: green- favored, yellow- disfavored; electrostatics: blue-favored, 
red- disfavored.  
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Figure A-11. Dipyridamole hENT4 CoMSIA steric and electrostatic contours 
 
Note: Color key. Steric: green- favored, yellow- disfavored; electrostatic: blue- favored, 
red-disfavored. 
 
 
 
 
 
Figure A-12. Dipyridamole hENT4 CoMSIA hydrophobic contours 
 
Note: Color key. Hydrophobic: yellow- favored, white- disfavored. 
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Figure A-13. Dipyridamole hENT4 CoMSIA hydrogen bond donor and acceptor 
contours 
 
Note: Color key. Hydrogen-bond donor: cyan- favored, purple- disfavored; hydrogen-
bond acceptor: magenta- favored, red- disfavored. 
 
 
hENT4 Flavone Models 
 
 
 
Figure A-14. Flavone hENT4 CoMFA contours 
 
Note: Color key. Steric: green- favored, yellow- disfavored; electrostatics: blue-favored, 
red- disfavored.  
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Figure A-15. Flavone hENT4 CoMSIA steric and electrostatic contours 
 
Note: Color key. Steric: green- favored, yellow- disfavored; electrostatic: blue- favored, 
red-disfavored. 
 
 
 
 
 
Figure A-16. Flavone hENT4 CoMSIA hydrophobic contours 
 
Note: Color key. Hydrophobic: yellow- favored, white- disfavored. 
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Figure A-17. Flavone hENT4 CoMSIA hydrogen bond donor and acceptor 
contours 
 
Note: Color key. Hydrogen-bond donor: cyan- favored, purple- disfavored; hydrogen-
bond acceptor: magenta- favored, red- disfavored. 
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Chemistry Data 
Mass Spectra 
 
Nucleoside Analogues 
 
 
 
Figure A-18. HCPN01 mass spectra 
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Figure A-19. HCPN05 mass spectra 
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Figure A-20. HCP09 mass spectra 
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Figure A-21. HCPN22 mass spectra 
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Figure A-22. HCPN29 mass spectra 
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Figure A-23. HCPN30 mass spectra 
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Figure A-24. HCPN34 mass spectra 
M+Na 
M+H 
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Figure A-25. HCPN58 mass spectra 
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Figure A-26. HCPN69 mass spectra 
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Figure A-27. HCPN78 mass spectra 
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Pyridone Analogues 
 
 
 
Figure A-28. Pyr2 mass spectra 
 
M- 
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Figure A-29. Pyr3 mass spectra 
 
 
 
 
(M+H)+1 
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Figure A-30. Pyr4 mass spectra 
 
 
 
 
 
 
  
M-1 
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NMR Spectra 
 
Nucleoside Analogues 
 
 
 
Figure A-31. HCPN01 proton NMR 
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Figure A-32. HCPN05 proton NMR 
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Figure A-33. HCPN09 proton NMR 
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Figure A-34. HCPN22 proton NMR 
. 
141 
 
 
Figure A-35. HCPN29 proton NMR 
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Figure A-36. HCPN30 proton NMR 
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Figure A-37. Expanded upfield section HCPN30 NMR 
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Figure A-38. HCPN34 proton NMR 
 
 
. 
145 
 
 
Figure A-39. HCPN58 expanded proton NMR 
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Figure A-40. HCPN58 proton NMR 
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Figure A-41. HCPN69 proton NMR 
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Figure A-42. HCPN78 proton NMR 
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Figure A-43. Expanded HCPN78 proton NMR 
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Pyridone Analogues 
 
 
 
Figure A-44. Pyr2 proton NMR 
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Figure A-45. Pyr3 proton NMR 
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Figure A-46. Expanded Pyr3 proton NMR 
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Figure A-47. Pyr4 proton NMR 
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Figure A-48. Pyr6 proton NMR 
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